var title_f14_8_14464="Color Doppler imaging of aortic dissection";
var content_f14_8_14464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color Doppler imaging of aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color flow mapping of type B dissection of the descending thoracic aorta using transesophageal echocardiography (0&deg; crystal orientation). There are differences in blood flow velocity on both sides of the intimal flap: the red color indicates blood flow in the true lumen (TL), while the lack of color indicates little or no flow in the false lumen (FL). The true and false lumen are defined by the respective presence or absence of an endothelial lining. The true lumen is best identified by imaging the proximal border of the dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD and Roberto Lang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14464=[""].join("\n");
var outline_f14_8_14464=null;
var title_f14_8_14465="Cefoperazone and sulbactam: International drug information";
var content_f14_8_14465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefoperazone and sulbactam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2225943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Sulbactam and Cefoperazone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2225944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2225945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Upper and lower respiratory and urinary tract infections; skin, soft tissue, bone and joint infections; septicemia, meningitis, peritonitis, cholecystitis, cholangitis, pelvic inflammatory disease, endometritis, gonorrhea, and other abdominal and genital tract infections",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2225947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For severe infections additional cefoperazone (without sulbactam), administered separately, may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., I.V.: Adults: 1-2 g (cefoperazone) every 12 hours; maximum daily dose: 4 g (sulbactam)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: 1 g every 12 hours; maximum daily dose: 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: 500 mg every 12 hours; maximum daily dose: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2227041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 1 g: cefoperazone sodium 0.5 g and sulbactam sodium 0.5 g; 2 g: cefoperazone sodium 1 g and sulbactam sodium 1 g",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10459 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14465=[""].join("\n");
var outline_f14_8_14465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2225943\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2225944\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2225945\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2225947\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821228\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2227041\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10459|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_8_14466="Normal human axoneme";
var content_f14_8_14466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal ciliary structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram of the normal human axoneme as it can be seen in respiratory cilia or sperm flagella.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Afzelius, BA. Genetics and pulmonary medicine. 6. Immotile cilia syndrome: past, present, and prospects for the future. Thorax 1998 53:894.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14466=[""].join("\n");
var outline_f14_8_14466=null;
var title_f14_8_14467="VISA questionnaire";
var content_f14_8_14467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    The VISA questionnaire: An index of severity of symptoms in patients with jumper's knee (patellar tendinosis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 762px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Visentini, PJ, Khan, KM, Cook, JL, et al. The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group. J Sci Med Sport 1998; 1:22. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14467=[""].join("\n");
var outline_f14_8_14467=null;
var title_f14_8_14468="Pelvic shapes";
var content_f14_8_14468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Four basic female pelvic types",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14468=[""].join("\n");
var outline_f14_8_14468=null;
var title_f14_8_14469="Potassium chloride: Patient drug information";
var content_f14_8_14469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium chloride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     see \"Potassium chloride: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/17/11542?source=see_link\">",
"     see \"Potassium chloride: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Tab&reg;;",
"     </li>",
"     <li>",
"      Kaon-CL&reg; 10;",
"     </li>",
"     <li>",
"      Klor-Con&reg;;",
"     </li>",
"     <li>",
"      Klor-Con&reg; 10;",
"     </li>",
"     <li>",
"      Klor-Con&reg; 8;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M10;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M15;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M20;",
"     </li>",
"     <li>",
"      Klor-Con&reg;/25;",
"     </li>",
"     <li>",
"      microK&reg;;",
"     </li>",
"     <li>",
"      microK&reg; 10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-K&reg;;",
"     </li>",
"     <li>",
"      K-10&reg;;",
"     </li>",
"     <li>",
"      K-Dur&reg;;",
"     </li>",
"     <li>",
"      Micro-K Extencaps&reg;;",
"     </li>",
"     <li>",
"      Roychlor&reg;;",
"     </li>",
"     <li>",
"      Slo-Pot;",
"     </li>",
"     <li>",
"      Slow-K&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12784410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium chloride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high potassium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use by mouth if you have a bowel block, slow-moving GI (gastrointestinal) tract, or slow stomach clearing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If water pill is stopped, potassium will most often be stopped too. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697601",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some products of potassium are in a wax matrix; you may see this in stool. The potassium has been taken into the body, but the wax has not.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix liquid or powder with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695271",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Klor-Con&reg; M: Tablet may be broken in half or the whole tablet may be mixed with a",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water. Drink it right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696110",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given. You may have to stop the tube feeding first. Some potassium products do not mix well with tube feeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10982 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-125.69.132.100-EF8B9C69FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14469=[""].join("\n");
var outline_f14_8_14469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211820\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211821\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12784410\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012624\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012623\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012628\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012629\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012631\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012626\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012627\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012632\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012633\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=related_link\">",
"      Potassium chloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/17/11542?source=related_link\">",
"      Potassium chloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_8_14470="Doxepin (topical): Drug information";
var content_f14_8_14470=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxepin (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/23/20852?source=see_link\">",
"    see \"Doxepin (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/54/14181?source=see_link\">",
"    see \"Doxepin (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8082212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prudoxin&trade;;",
"     </li>",
"     <li>",
"      Zonalon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zonalon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8082545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8082326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Burning mouth syndrome (unlabeled use):",
"     </b>",
"     Oral topical: Cream: Apply 3-4 times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pruritus:",
"     </b>",
"     Topical: Apply a thin film 4 times/day with at least 3- to 4-hour interval between applications; not recommended for use &gt;8 days. (Oral administration of doxepin 25-50 mg has also been used, but systemic adverse effects are increased.)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8082327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pruritus: Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prudoxin&trade;: 5% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zonalon&reg;: 5% (30 g, 45 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8082330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Apply thin film to affected area; use of occlusive dressings is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8082221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Short-term (&lt;8 days) management of moderate pruritus in adults with atopic dermatitis or lichen simplex chronicus",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10881644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cream: Treatment of burning mouth syndrome and neuropathic pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxepin may be confused with digoxin, doxapram, doxazosin, Doxidan&reg;, doxycycline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zonalon&reg; may be confused with Zone-A&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal [Finland] may be confused with Doxil brand name for doxorubicin (liposomal) [U.S.,  Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal brand name for doxepin [Finland] but also brand name for pyridoxine/thiamine [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8082252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Stinging/burning (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema: (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%), emotional changes (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (10%), taste alteration (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Contact dermatitis, tongue numbness, anxiety",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8082248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxepin, drugs from similar chemical class, or any component of the formulation; narrow-angle glaucoma; urinary retention; use of MAO inhibitors within 14 days; use in a patient during acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8082249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: Cream formulation is for external use only (not for ophthalmic, vaginal, or oral use). Do not use occlusive dressings. Use for &gt;8 days may increase risk of contact sensitization. Doxepin is significantly absorbed following topical administration; plasma levels may be similar to those achieved with oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8082244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8082245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Following topical application, plasma levels may be similar to those achieved with oral administration",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8082246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9890219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness and apnea have been reported in a nursing infant following maternal use of oral doxepin. Following topical application, plasma levels may be similar to those achieved with oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8082340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Prudoxin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (45 g): $209.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Zonalon External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (30 g): $208.93",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8082332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects may be increased if topical formulation is applied to &gt;10% of body surface area",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8082292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Absorption: Following topical application, plasma levels may be similar to those achieved with oral administration",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/8/14470/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buchanan J and Zakrzewska J, &ldquo;Burning Mouth Syndrome,&rdquo;",
"      <i>",
"       Clin Evid (online)",
"      </i>",
"      , March 14, 2008. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/8/14470/abstract-text/19450321/pubmed\" id=\"19450321\" target=\"_blank\">",
"        19450321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&iacute;nguez Serra MP, Salort Llorca C, Silvestre Donat FJ, \"Pharmacological Treatment of Burning Mouth Syndrome: A Review and Update,\"",
"      <i>",
"       Med Oral Patol Oral Cir Bucal",
"      </i>",
"      , 2007, 12(4):E299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/8/14470/abstract-text/17664916/pubmed\" id=\"17664916\" target=\"_blank\">",
"        17664916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9113 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14470=[""].join("\n");
var outline_f14_8_14470=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082218\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082545\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082326\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082327\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082338\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082220\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082330\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082221\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10881644\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082209\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082252\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082248\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082249\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082256\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082244\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082245\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082246\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9890219\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082340\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082332\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082292\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9113\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9113|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/32/44551?source=related_link\">",
"      Doxepin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/8/40069?source=related_link\">",
"      Doxepin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/59/24503?source=related_link\">",
"      Doxepin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/23/20852?source=related_link\">",
"      Doxepin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/54/14181?source=related_link\">",
"      Doxepin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_8_14471="Endoscopic ultrasound guided trucut biopsy";
var content_f14_8_14471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic ultrasound guided trucut biopsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14471/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14471/contributors\">",
"     Michael J Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14471/contributors\">",
"     Maurits J Wiersema, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14471/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14471/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14471/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/8/14471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 2, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) is a useful method for evaluating intra- and extra-intestinal mass lesions, and peri-intestinal lymphadenopathy. EUS guided fine needle aspiration (FNA) can be performed at the same time as the diagnostic examination and offers a diagnostic accuracy of 60 to 90 percent depending upon the site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, EUS FNA is associated with several limitations. It may not always be possible to assess the adequacy of sampling during the procedure and cytologic interpretation can be hampered by the presence of blood and benign epithelial cells. Furthermore, tumors that are well differentiated or contain substantial desmoplasia are more difficult to diagnose using cytology alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/1\">",
"     1",
"    </a>",
"    ]. Finally, EUS FNA typically yields a small biopsy sample and destroys the tissue architecture, thereby limiting diagnostic accuracy for lesions such as gastrointestinal stromal tumors (GIST) and lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger caliber cutting needles were designed to overcome many of the problems associated with FNA. These needles acquire larger tissue specimens thereby preserving tissue architecture and permitting histologic rather than only cytologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/4-11\">",
"     4-11",
"    </a>",
"    ]. Several studies have demonstrated that large caliber cutting needles are safe and accurate when used percutaneously, intraluminally, or surgically for diagnosing lesions arising in soft tissue, breast, lung, lymph node, pancreas, liver, kidney, adrenal, spleen, prostate, and other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/11-23\">",
"     11-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple initial attempts were made to adapt a needle system that could be used with the echoendoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. None was successful until the development of the trucut biopsy (TCB) needle (Quick-Core, Cook Endoscopy, Winston-Salem, North Carolina), which could be used with linear echoendoscopes.",
"   </p>",
"   <p>",
"    Initial studies suggest greater diagnostic accuracy of EUS TCB compared with EUS FNA for submucosal mass lesions and lymphoma, and potentially the need for fewer needle passes for diagnosis of solid pancreatic neoplasms. Small studies have also demonstrated the potential to establish a diagnosis in a variety of disorders that would traditionally have required surgery.",
"   </p>",
"   <p>",
"    This topic review will summarize clinical experience with EUS TCB. A discussion on EUS FNA is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEVICE DESIGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCB device contains a spring-loaded mechanism built into the handle that permits automated procurement of biopsy specimens (",
"    <a class=\"graphic graphic_picture graphicRef56460 \" href=\"UTD.htm?39/24/40321\">",
"     picture 1",
"    </a>",
"    ). As with EUS FNA needles, an adjustable \"screw-stop lock\" is incorporated into the handle, and when unlocked, allows advancement up to 8 cm. The handle also incorporates an \"adjustment wheel\" that rotates the device into the proper orientation and slightly varies the length. In addition, a \"spacer\" can be added to allow for the variation in echoendoscope length among manufacturers. The non-handle portion of the TCB device consists of an outer catheter sheath, an internal 19 gauge cutting sheath, an 18 mm long specimen tray, and a 5 mm long stylet tip (",
"    <a class=\"graphic graphic_picture graphicRef70296 \" href=\"UTD.htm?13/50/14112\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEVICE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial preparation is required prior to insertion of the TCB device in the echoendoscope. Doing so requires retraction of the handle into the firing position (",
"    <a class=\"graphic graphic_picture graphicRef79541 \" href=\"UTD.htm?29/21/30032\">",
"     picture 3",
"    </a>",
"    ), which retracts both the cutting sheath and specimen tray. The inner needle remains in the withdrawn position until the biopsy is performed. The needle is then advanced until the tip is nearly flush with the catheter sheath (",
"    <a class=\"graphic graphic_picture graphicRef60008 \" href=\"UTD.htm?35/22/36193\">",
"     picture 4",
"    </a>",
"    ). Incomplete advancement of the needle tip may result in inadvertent puncture of the catheter and echoendoscope while over advancement risks damage to the echoendoscope's accessory channel. Once the TCB device is properly prepared, it is advanced through the echoendoscope and screwed securely into the biopsy channel Luer-lock adapter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIOPSY TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The needle is carefully advanced under real time EUS visualization with the spring handle in the retracted firing position. The spring handle is then pressed forward until resistance is felt, thereby advancing the specimen tray into the target lesion. When targeting the biopsy, the operator must be aware that the specimen tray will extend approximately 20 mm beyond the needle tip. Further pressure on the spring handle will fire the device and obtain a biopsy.",
"   </p>",
"   <p>",
"    All controls (up-down and left-right) and the elevator should be released into a \"relaxed\" position. Subsequent biopsy requires full depression of the plunger in the direction of the accessory channel. This action serves to spring fire the cutting sheath over the specimen tray.",
"   </p>",
"   <p>",
"    Distinct echo features are discernible for the cutting sheath and specimen tray (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77390 \" href=\"UTD.htm?11/60/12229\">",
"     image 1",
"    </a>",
"    ). This permits imaging of the specimen tray within the target tissue, thereby allowing the operator to monitor each step under continuous EUS imaging. The needle assembly is withdrawn into the catheter, the screw-stop is locked, and the entire TCB device is removed from the endoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPECIMEN HANDLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;To retrieve the tissue from the specimen tray, the screw-stop is unlocked and the needle assembly (cutting sheath and internal specimen tray) is fully advanced. The spring handle is then retracted until it clicks into the firing position, which retracts both the outer cutting sheath and inner needle specimen tray. The spring handle is advanced until resistance is felt. This action advances the inner specimen tray to expose the biopsy tissue.",
"   </p>",
"   <p>",
"    Once resistance is felt, the operator should discontinue pressing the plunger to avoid inadvertent firing. A needle is used to carefully remove the specimen from the specimen tray or one may simply place a tissue pad against the specimen to remove it (",
"    <a class=\"graphic graphic_picture graphicRef77967 \" href=\"UTD.htm?36/22/37216\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79040 \" href=\"UTD.htm?42/28/43462\">",
"     picture 6",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    If needed, touch preps are made from the histologic core. The touch prep is prepared by gently touching a glass slide against the core of tissue. An on-site cytopathologist or cytotechnologist can thereby provide an assessment of the adequacy of sampling. The TCB biopsy tissue cores are fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin prior to histological examination. When lymphoma is suspected, some material should be preserved in saline or another suitable media recommended by pathology for flow cytometry studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EUS TCB TECHNICAL DETAILS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several issues arise with the TCB needles that differ from EUS FNA. Careful attention to these details is particularly important if initial biopsies are inadequate or non-diagnostic. The points of emphasis include: (1) site of TCB, (2) proper device rotational orientation, (3) targeting, and (4) straightening of the echoendoscope and needle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Site of EUS TCB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCB needle functions well in the esophagus, rectum, and most of the stomach. Performing EUS TCB is difficult and less often yields an adequate specimen when used in the fundus, antrum, and duodenal bulb and is not recommended beyond the apex of the bulb. In all of these locations, echoendoscope angulation produces sluggish advancement of the cutting sheath over the specimen tray. Although EUS TCB is impaired in certain locations, this does not appear to result in increased patient risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Proper device rotational orientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper device orientation can improve tissue collection, which is performed by rotating the needle so that the 19-gauge marker on the TCB device is aligned with the model number on the echoendoscope handle (",
"    <a class=\"graphic graphic_picture graphicRef74755 \" href=\"UTD.htm?43/12/44225\">",
"     picture 7",
"    </a>",
"    ) Correct orientation of the handle results in alignment of the specimen tray so that it directly faces the transducer. We have found that some variation in biopsy channel alignment exists within the same model of echoendoscopes, thereby requiring individual assessment for the proper needle orientation. Once determined, it can be used consistently for that instrument. However, if the echoendoscope undergoes repair, this alignment may change and require some adjustment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Targeting",
"    </span>",
"    &nbsp;&mdash;&nbsp;When initially advancing the needle, the 18 mm long specimen tray and 1 mm of the distal stylet are retracted and contained within the cutting sheath. As a result, when the spring handle is pressed, the device will advance another 19 mm, potentially leading to traversal of the lesion and puncture of adjacent structures. This is of particular concern for small lesions and those juxtaposed to a vascular structure.",
"   </p>",
"   <p>",
"    Such lesions can often be safely biopsied by only partially advancing the specimen tray into the lesion so that some of the specimen tray is within more superficial tissues",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the luminal mucosa. Caution is advised with this approach due to the potential for echoendoscope damage.",
"   </p>",
"   <p>",
"    Another approach for the biopsy of smaller lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superficial lesions is to advance the specimen tray deeper than usual so that the specimen tray overlaps both the target tissue and deeper tissues. The safety of this approach depends upon the tissue underlying the target lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Straightening of the echoendoscope and needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keeping the echoendoscope and needle straightened as much as possible, both within and outside of the patient, facilitates tissue acquisition. Elevator and tip deflection should be minimal. Once the target lesion is entered, the controls should be relaxed; failing to do so results in sluggish advancement of the cutting sheath over the specimen tray. Attention to each of these technical aspects enhances tissue acquisition and may improve patient safety and minimize instrument damage. These considerations may limit the ability to target lesions in areas where only a sharply angled endoscopic alignment is possible, a frequent occurrence in the proximal stomach and duodenum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFICACY AND SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with EUS TCB is accumulating rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/26-38\">",
"     26-38",
"    </a>",
"    ]. While the available data have not clearly demonstrated superiority to EUS FNA, EUS TCB may be more effective for diagnosis of submucosal mass lesions and lymphoma, potentially avoiding the need for more aggressive diagnostic or therapeutic procedures. Furthermore, EUS TCB generally requires fewer needle passes compared with EUS FNA. Regarding safety, in one large series of 247 patients, the overall complication rate was 2 percent, which is similar to that reported with EUS FNA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/38\">",
"     38",
"    </a>",
"    ]. The following will summarize the largest reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intra- and extra-intestinal mass lesions and lymphadenopathy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following initial successful studies in pigs, our group reported the initial experience in humans, comparing the accuracy and safety of EUS TCB with EUS FNA for intra- and extra-intestinal mass lesions and peri-intestinal lymphadenopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. In a report published as an abstract, 46 patients underwent biopsy with both EUS TCB and EUS FNA of 47 sites (two sites in one patient) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/29\">",
"       29",
"      </a>",
"      ]. A total of 104 needle passes were performed during EUS TCB (mean 2.21 passes per lesion [SD 0.83], range 1 to 8), and 170 passes were made during EUS FNA (mean 3.62 passes per lesion [SD 1.63], range 1 to 12). The final diagnoses were pancreas neoplasm (n = 15), malignant lymph node (n = 12), intramural",
"      <span class=\"nowrap\">",
"       tumor/submucosal",
"      </span>",
"      mass (n = 11), benign lymph node (n = 7), liver mass (n = 1), and extramural mass (n = 1). The accuracy of EUS TCB was higher than EUS FNA (85 versus 62 percent) despite performing significantly fewer needle passes, although the differences in accuracy did not achieve statistical significance. No complications were identified with either device.",
"      <br/>",
"      <br/>",
"      The greater accuracy of EUS TCB was almost entirely accounted for by the biopsy of submucosal mass lesions (n = 11) and lymphoma (n = 6). In this subgroup, the accuracy of EUS TCB was",
"      <span class=\"nowrap\">",
"       15/17",
"      </span>",
"      (88 percent) compared with EUS FNA",
"      <span class=\"nowrap\">",
"       5/17",
"      </span>",
"      (29 percent). We concluded that EUS TCB can safely biopsy intra- and extra-intestinal lesions and lymphadenopathy and may require fewer needle passes than EUS FNA.",
"     </li>",
"     <li>",
"      The diagnostic accuracy of EUS TCB was evaluated in 18 patients in whom EUS FNA yielded inadequate or non-diagnostic tissue based upon preliminary \"in room\" cytologic review or in whom there was suspicion for pathology (stromal tumor, sarcoidosis, or lymphoma) for which histological morphology was preferred [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/30\">",
"       30",
"      </a>",
"      ]. Despite a study design favoring EUS TCB, the diagnostic accuracy was higher for EUS FNA (89 percent versus 78).",
"      <br/>",
"      <br/>",
"      Two patients developed complications. One developed bleeding after TCB of a gastric stromal tumor that was successfully managed by endoscopic injection of epinephrine, while a second patient developed mediastinitis following EUS TCB (three passes) of a bronchogenic cyst that required surgical drainage. However, in the latter patient, EUS FNA (six passes) was also performed leaving uncertainty regarding the causal role of TCB.",
"     </li>",
"     <li>",
"      The overall diagnostic accuracy of EUS TCB was 61 percent in a prospective study of 23 patients with a solid pancreatic mass [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/31\">",
"       31",
"      </a>",
"      ]. EUS TCB was technically successful in all 13 patients undergoing transgastric biopsy of a pancreatic body or tail lesion. However, EUS TCB was successful in only 4 of 10 patients (40 percent) undergoing transduodenal biopsy of a mass within the pancreatic head.",
"      <br/>",
"      <br/>",
"      The authors believed that the degree of echoendoscope tip deflection required to access the target lesion precluded extension of the needle from the accessory channel. This differs from our experience in that needle advancement into the target tissue is usually possible even with a transduodenal approach, but \"sluggish\" advancement of the cutting sheath over the specimen tray is what precludes acquisition of a diagnostic sample. When excluding those in whom EUS TCB was not technically possible and those lost to follow-up, the correct diagnosis was established in 87 percent of patients.",
"      <br/>",
"      <br/>",
"      In addition to EUS TCB, EUS FNA was also performed in 12 patients agreeing to undergo both biopsy procedures. For this group, EUS TCB and EUS FNA established the correct diagnosis in 10 (83 percent) and 6 (50 percent) patients, respectively. In addition, the number of TCB needed to establish the diagnosis (1.4 (range 1 to 3)) for the entire study population was fewer than required for EUS FNA (3.0 (range 2 to 5)) for this subgroup. The average number of TCB for the subgroup of patients undergoing both TCB and FNA was not specified. No complications were described.",
"     </li>",
"     <li>",
"      We prospectively assessed the malignancy detection rate and safety of EUS TCB and investigated whether EUS FNA is useful as a rescue technique in cases of TCB failure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients with a known or suspected malignancy referred for diagnostic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      staging EUS exam were prospectively enrolled. If EUS TCB failed to obtain an adequate sample or when the \"in room\" touch-prep suggested that the lesion was benign, EUS FNA was performed with a standard 22-gauge FNA needle.",
"      <br/>",
"      <br/>",
"      Thirty patients with a total of 39 lesions underwent EUS TCB. Sufficient follow-up was available for all patients. Biopsied lesions included lymphadenopathy (n = 19), pancreatic mass (n = 12), liver metastasis (n = 3), perigastric or mediastinal mass (n = 2), submucosal tumor (n = 2), and esophageal tumor (n = 1). Thirty-one lesions were malignant and eight were benign. The malignancy detection rate for EUS TCB was 87 percent",
"      <span class=\"nowrap\">",
"       (27/31)",
"      </span>",
"      (95% confidence interval 74-96 percent). EUS TCB was unable to establish the correct diagnosis in 5 of 39 lesions (13 percent) as a result of failure to obtain an adequate sample due to technical difficulties (n = 3) or due to a false negative result for malignancy (n = 2).",
"      <br/>",
"      <br/>",
"      For these five patients with a failed diagnosis, three had a pancreatic mass, and two had lymphadenopathy. In four of five patients with failed EUS TCB diagnosis, EUS FNA established the correct diagnosis. In the remaining patient, EUS TCB of a second site (primary pancreatic tumor) allowed diagnosis.",
"      <br/>",
"      <br/>",
"      One patient developed minimal, clinically insignificant bleeding at the site of EUS TCB as detected during the EUS exam. The appearance was identical to that for post EUS FNA bleeding as we previously described [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/33\">",
"       33",
"      </a>",
"      ]. No complications were recorded in any patients during the 1 and 7 day follow-up. We concluded that EUS TCB is a safe and accurate modality for diagnosing gastrointestinal malignancies and that EUS FNA serves as a reliable rescue technique in cases of trucut failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cystic pancreatic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;We studied 10 patients with a cystic pancreatic lesion who underwent EUS TCB (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81953 \" href=\"UTD.htm?21/33/22034\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59882 \" href=\"UTD.htm?25/62/26599\">",
"     picture 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/34\">",
"     34",
"    </a>",
"    ]. The final diagnosis (based upon clinical, laboratory, imaging and biopsy findings, and resected specimens when available) included serous cystadenoma (SCA, n = 5), islet cell tumor (n = 2), mixed seromucinous lesion (n = 1), polycystic disease of the pancreas (n = 1), and pseudocyst (n = 1). EUS TCB was non-diagnostic in 3 of 10 patients (one each with a SCA, polycystic disease, and pseudocyst). Among the other seven patients, TCB diagnosed four SCAs, obviating the need for planned surgery in three of the four patients. In the fourth patient with an SCA, the TCB result ruled-out metastatic disease from locally recurrent lung cancer, thereby allowing a more narrowed field of radiation. EUS TCB also confirmed the need for surgery in two patients with an islet cell tumor. In one patient, EUS TCB findings were suspicious leading to previously unplanned surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Autoimmune pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS FNA is insufficient to diagnose autoimmune pancreatitis (AIP) due to the small sample size and lack of tissue architecture. We evaluated five patients in whom the diagnosis was considered; a mean of 2.8 EUS TCBs (range 2-5) was obtained per patient [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/34\">",
"     34",
"    </a>",
"    ]. TCB specimens were diagnostic of AIP in two patients and were strongly suggestive but not diagnostic in two others. In one patient only nonspecific changes of chronic pancreatitis were seen on histology. EUS FNA (mean 4.3 passes, range 2-7 passes) was performed in four of five patients and failed to establish or suggest the diagnosis in any of these patients. Other than mild transient abdominal pain (n = 1) no complications were identified. None of the patients underwent the initially planned resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS TCB does not appear to have a role in the diagnosis of suspected nonfocal chronic pancreatitis because of complications and limited diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14471/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for EUS TCB are evolving. Clinical experience is limited, while the available studies have included only small numbers of patients, generally did not use a standard protocol regarding the number of passes with FNA and TCB, did not always thoroughly describe the indications for performing TCB, and were not randomized or blinded. Despite these limitations, the data suggest that EUS TCB is safe.",
"   </p>",
"   <p>",
"    While superiority to EUS FNA has not been clearly demonstrated, EUS TCB may be more accurate than EUS FNA in diagnosing submucosal lesions and lymphadenopathy thought to be due to lymphoma or inflammatory conditions. It may also have a role in diagnosis of other lesions where preservation of architectural features is particularly important.",
"   </p>",
"   <p>",
"    The role of EUS TCB in our practice has expanded over time. We initially performed EUS TCB when EUS FNA specimens were inadequate or non-diagnostic. We now favor TCB for a variety of indications and often as the initial means of biopsy for submucosal tumors and suspected lymphoma. We also favor EUS TCB over EUS FNA for evaluation of solid pancreatic mass lesions (in the pancreatic neck, body, and tail that are accessible from the stomach). In patients with a pancreatic cystic lesion or suspected autoimmune pancreatitis, we initially perform TCB using EUS FNA when TCB is unsuccessful.",
"   </p>",
"   <p>",
"    In all other situations we consider FNA the favored EUS diagnostic modality. Patient characteristics, endosonographer experience, and available expertise for cytologic and histologic review will influence use of both devices. EUS FNA and EUS TCB should not necessarily be regarded as competing modalities, but rather as complimentary.",
"   </p>",
"   <p>",
"    We consider any of the following to be absolute contraindications for EUS TCB:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location of the target lesion prohibiting biopsy",
"     </li>",
"     <li>",
"      Presence of intervening structures prohibiting biopsy",
"     </li>",
"     <li>",
"      Uncorrectable coagulopathy (INR &gt;1.5)",
"     </li>",
"     <li>",
"      Uncorrectable thrombocytopenia (platelets &lt;50,000)",
"     </li>",
"     <li>",
"      An uncooperative patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications include a less than ideal location of target lesion making TCB more difficult and altered anatomy prohibiting access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the role of EUS TCB is evolving. Large, prospective studies comparing EUS TCB to EUS FNA are needed to more clearly establish the accuracy, role, safety, and cost-effectiveness of TCB.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial studies suggest greater diagnostic accuracy of EUS TCB compared with EUS FNA for submucosal lesions and lymphomas because of the opportunity for histologic review.",
"     </li>",
"     <li>",
"      The TCB needle functions well in the esophagus, rectum, and most of the stomach. Performing EUS TCB is difficult and less often yields an adequate specimen when used in the fundus, antrum, and duodenal bulb and is not recommended beyond the apex of the bulb.",
"     </li>",
"     <li>",
"      EUS TCB may have a role in diagnosis of cystic pancreatic lesions and autoimmune pancreatitis.",
"     </li>",
"     <li>",
"      EUS TCB generally requires fewer needle passes than EUS FNA, especially for solid pancreatic neoplasms. Whether this leads to improved safety remains to be determined.",
"     </li>",
"     <li>",
"      Contraindications to EUS TCB are described above. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/1\">",
"      Wiersema MJ, Vilmann P, Giovannini M, et al. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 1997; 112:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/2\">",
"      Ribeiro A, Vazquez-Sequeiros E, Wiersema LM, et al. EUS-guided fine-needle aspiration combined with flow cytometry and immunocytochemistry in the diagnosis of lymphoma. Gastrointest Endosc 2001; 53:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/3\">",
"      Erickson RA, Sayage-Rabie L, Beissner RS. Factors predicting the number of EUS-guided fine-needle passes for diagnosis of pancreatic malignancies. Gastrointest Endosc 2000; 51:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/4\">",
"      Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/5\">",
"      Kovalik EC, Schwab SJ, Gunnells JC, et al. No change in complication rate using spring-loaded gun compared to traditional percutaneous renal allograft biopsy techniques. Clin Nephrol 1996; 45:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/6\">",
"      Brandt KR, Charboneau JW, Stephens DH, et al. CT- and US-guided biopsy of the pancreas. Radiology 1993; 187:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/7\">",
"      Welch TJ, Sheedy PF 2nd, Johnson CD, et al. CT-guided biopsy: prospective analysis of 1,000 procedures. Radiology 1989; 171:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/8\">",
"      Harrison BD, Thorpe RS, Kitchener PG, et al. Percutaneous Trucut lung biopsy in the diagnosis of localised pulmonary lesions. Thorax 1984; 39:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/9\">",
"      Ingram DM, Sheiner HJ, Shilkin KB. Operative biopsy of the pancreas using the Trucut needle. Aust N Z J Surg 1978; 48:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/10\">",
"      Lavelle MA, O'Toole A. Trucut biopsy of the prostate. Br J Urol 1994; 73:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/11\">",
"      Ball AB, Fisher C, Pittam M, et al. Diagnosis of soft tissue tumours by Tru-Cut biopsy. Br J Surg 1990; 77:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/12\">",
"      Zinzani PL, Colecchia A, Festi D, et al. Ultrasound-guided core-needle biopsy is effective in the initial diagnosis of lymphoma patients. Haematologica 1998; 83:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/13\">",
"      Hatada T, Ishii H, Ichii S, et al. Diagnostic value of ultrasound-guided fine-needle aspiration biopsy, core-needle biopsy, and evaluation of combined use in the diagnosis of breast lesions. J Am Coll Surg 2000; 190:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/14\">",
"      Radhakrishnan V. Transrectal Tru-cut biopsy of the prostate using a protective sheath. Br J Urol 1994; 73:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/15\">",
"      Rodr&iacute;guez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998; 160:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/16\">",
"      Durup Scheel-Hincke J, Mortensen MB, Pless T, Hovendal CP. Laparoscopic four-way ultrasound probe with histologic biopsy facility using a flexible tru-cut needle. Surg Endosc 2000; 14:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/17\">",
"      Indinnimeo M, Cicchini C, Stazi A, et al. Trans anal full thickness tru-cut needle biopsies in anal canal tumors after conservative treatment. Oncol Rep 1998; 5:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/18\">",
"      Sada PN, Ramakrishna B, Thomas CP, et al. Transjugular liver biopsy: a comparison of aspiration and trucut techniques. Liver 1997; 17:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/19\">",
"      Chau TN, Tong SW, Li TM, et al. Transjugular liver biopsy with an automated trucut-type needle: comparative study with percutaneous liver biopsy. Eur J Gastroenterol Hepatol 2002; 14:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/20\">",
"      Tweedle DE. Peroperative transduodenal biopsy of the pancreas. Gut 1979; 20:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/21\">",
"      Johnson CD, Stephens DH, Charboneau JW, et al. Cystic pancreatic tumors: CT and sonographic assessment. AJR Am J Roentgenol 1988; 151:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/22\">",
"      Nyman RS, Cappelen-Smith J, Brismar J, et al. Yield and complications in ultrasound-guided biopsy of abdominal lesions. Comparison of fine-needle aspiration biopsy and 1.2-mm needle core biopsy using an automated biopsy gun. Acta Radiol 1995; 36:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/23\">",
"      B&ouml;cking A, Klose KC, Kyll HJ, Hauptmann S. Cytologic versus histologic evaluation of needle biopsy of the lung, hilum and mediastinum. Sensitivity, specificity and typing accuracy. Acta Cytol 1995; 39:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/24\">",
"      Wiersema MJ, Jondal ML, Schwartz DA, et al. Prospective comparison of a 19- versus 22-gauge needle for performing EUS-FNA of pancreas mass lesions: assessment of accuracy and factors influencing safety (abstract). Gastrointest Endosc 2002; 55:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/25\">",
"      Caletti GC, Brocchi E, Ferrari A, et al. Guillotine needle biopsy as a supplement to endosonography in the diagnosis of gastric submucosal tumors. Endoscopy 1991; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/26\">",
"      Fern&aacute;ndez-Esparrach G, Sendino O, Sol&eacute; M, et al. Endoscopic ultrasound-guided fine-needle aspiration and trucut biopsy in the diagnosis of gastric stromal tumors: a randomized crossover study. Endoscopy 2010; 42:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/27\">",
"      Wiersema MJ, Levy MJ, Harewood GC, et al. Initial experience with EUS-guided trucut needle biopsies of perigastric organs. Gastrointest Endosc 2002; 56:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/28\">",
"      Levy MJ, Jondal ML, Clain J, Wiersema MJ. Preliminary experience with an EUS-guided trucut biopsy needle compared with EUS-guided FNA. Gastrointest Endosc 2003; 57:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/29\">",
"      Levy MJ, Wiersema MJ, Clain JE, et al. Comparison of endoscopic ultrasound-guided trucut biopsy (EUS-TCB) to endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) (abstract W1228). Gastrointest Endosc 2003; 57:AB244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/30\">",
"      Varadarajulu S, Fraig M, Schmulewitz N, et al. Comparison of EUS-guided 19-gauge Trucut needle biopsy with EUS-guided fine-needle aspiration. Endoscopy 2004; 36:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/31\">",
"      Larghi A, Verna EC, Stavropoulos SN, et al. EUS-guided trucut needle biopsies in patients with solid pancreatic masses: a prospective study. Gastrointest Endosc 2004; 59:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/32\">",
"      Gin&egrave;s A, Wiersema MJ, Clain JE, et al. Prospective study of a Trucut needle for performing EUS-guided biopsy with EUS-guided FNA rescue. Gastrointest Endosc 2005; 62:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/33\">",
"      Affi A, Vazquez-Sequeiros E, Norton ID, et al. Acute extraluminal hemorrhage associated with EUS-guided fine needle aspiration: frequency and clinical significance. Gastrointest Endosc 2001; 53:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/34\">",
"      Levy MJ, Smyrk TC, Reddy RP, et al. Endoscopic ultrasound-guided trucut biopsy of the cyst wall for diagnosing cystic pancreatic tumors. Clin Gastroenterol Hepatol 2005; 3:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/35\">",
"      DeWitt J, McGreevy K, LeBlanc J, et al. EUS-guided Trucut biopsy of suspected nonfocal chronic pancreatitis. Gastrointest Endosc 2005; 62:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/36\">",
"      Storch I, Jorda M, Thurer R, et al. Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination. Gastrointest Endosc 2006; 64:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/37\">",
"      Kien-Fong Vu C, Chang F, Doig L, Meenan J. A prospective control study of the safety and cellular yield of EUS-guided FNA or Trucut biopsy in patients taking aspirin, nonsteroidal anti-inflammatory drugs, or prophylactic low molecular weight heparin. Gastrointest Endosc 2006; 63:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14471/abstract/38\">",
"      Thomas T, Kaye PV, Ragunath K, Aithal G. Efficacy, safety, and predictive factors for a positive yield of EUS-guided Trucut biopsy: a large tertiary referral center experience. Am J Gastroenterol 2009; 104:584.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2649 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14471=[""].join("\n");
var outline_f14_8_14471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEVICE DESIGN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEVICE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIOPSY TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPECIMEN HANDLING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EUS TCB TECHNICAL DETAILS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Site of EUS TCB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Proper device rotational orientation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Targeting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Straightening of the echoendoscope and needle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFICACY AND SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intra- and extra-intestinal mass lesions and lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cystic pancreatic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2649|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/60/12229\" title=\"diagnostic image 1\">",
"      Trucut apparatus seen by EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/33/22034\" title=\"diagnostic image 2\">",
"      Serous cystadenoma EUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2649|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/24/40321\" title=\"picture 1\">",
"      Trucut EUS apparatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/50/14112\" title=\"picture 2\">",
"      Trucut needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/21/30032\" title=\"picture 3\">",
"      Trucut spring loaded handle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/22/36193\" title=\"picture 4\">",
"      Preparation catheter sheath",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/22/37216\" title=\"picture 5\">",
"      Tissue core Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/28/43462\" title=\"picture 6\">",
"      EUS biopsy core Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/12/44225\" title=\"picture 7\">",
"      Orientation adjuster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/62/26599\" title=\"picture 8\">",
"      Serous cystadenoma Light III",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_8_14472="Recurrent pyogenic cholangitis";
var content_f14_8_14472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recurrent pyogenic cholangitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14472/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14472/contributors\">",
"     Hannah Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14472/contributors\">",
"     Kris V Kowdley, MD, FACP, FACG, FASGE, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14472/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14472/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14472/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/8/14472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent pyogenic cholangitis is a disease characterized by intrabiliary pigment stone formation, resulting in stricturing of the biliary tree and biliary obstruction with recurrent bouts of cholangitis. Various other names have been used since the first description in 1930, including Hong Kong disease, biliary obstruction syndrome of the Chinese, Oriental cholangitis, and Oriental infestational cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/1\">",
"     1",
"    </a>",
"    ]. The lack of a uniform nomenclature complicates direct comparison of studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent pyogenic cholangitis is found almost exclusively in people who live or who have lived in Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. However, the incidence in the West appears to be increasing due to the immigration of people from endemic countries. It occurs in equal frequency in men and women with a peak prevalence in the third and fourth decades of life, although it can also be seen in patients over the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. It is more common in the rural population and in lower socioeconomic groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent pyogenic cholangitis is characterized by recurrent cholangitis caused by bile stasis and stone formation proximal to biliary strictures. The pathogenesis of the stone formation and biliary abnormalities is incompletely understood. Stone formation occurs de novo within the intrahepatic bile ducts in contrast with the more common pattern of stone formation within the gallbladder seen in patients with more common forms of gallstone-related disease.",
"   </p>",
"   <p>",
"    Transient portal bacteremia is thought to introduce bacteria into the biliary ducts, initiating a cycle of infection and secondary stone formation which lead to further obstruction and infection. Common organisms cultured from bile include E. coli, Klebsiella, Pseudomonas, and Proteus species and, less frequently, anaerobes, although the culture of multiple organisms is common [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Abnormal phospholipid metabolism has also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bile ducts are markedly abnormal, characterized by extrahepatic and intrahepatic ductal dilatation with focal areas of stricturing in the intrahepatic biliary tree. The biliary wall is fibrotic with inflammatory cell infiltration. The bile is purulent and filled with debris, composed of bile pigment, desquamated epithelial cells, bacteria, and pus.",
"   </p>",
"   <p>",
"    The left hepatic duct, especially the left lateral segmental duct, is usually affected in the early course of the disease, although stones may be present in the right and left hepatic lobes and the extrahepatic biliary tree [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/14\">",
"     14",
"    </a>",
"    ]. The reason why the left ductal system is more commonly involved is unknown. A possible explanation may be that the left hepatic ducts come off at a more acute angle compared with the right hepatic ducts, thus predisposing to stasis and stricture formation.",
"   </p>",
"   <p>",
"    There are often innumerable stones of varying sizes. The stones are mainly composed of calcium bilirubinate or brown pigment in contrast to the cholesterol stones more commonly seen in patients with other gallstone-related diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other changes that may be seen include hypertrophy of the papilla of the sphincter of Oddi as the result of repeated passage of stones, and enlargement and scarring of the liver with multiple capsular adhesions or deep subcapsular abscesses. The liver may eventually atrophy because of multiple episodes of infection and inflammation, leaving segments containing nothing more than fibrous tissue and dilated ducts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of recurrent pyogenic cholangitis is unknown, although many theories have been proposed. The observation that the disease occurs mainly in southeast Asia and among the rural, lower socioeconomic population suggests that environmental factors have an important role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Parasitic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geographic clustering of recurrent pyogenic cholangitis in regions where biliary parasites are endemic has implicated biliary parasitosis (mainly liver flukes and the roundworm Ascaris) in its pathogenesis. The three major liver trematodes or flukes that infect humans are Clonorchis sinensis, Opisthorchis species, and Fasciola hepatica. These organisms can cause epithelial damage and biliary obstruction, possibly initiating the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C. sinensis, also known as the Chinese liver fluke, is endemic in the East, particularly in China, Japan, Taiwan, Vietnam, and Korea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10648?source=see_link\">",
"       \"Liver flukes: Clonorchiasis and opisthorchiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The two species that most frequently cause human opisthorchiasis are O. felineus and O. viverrini. O. felineus occurs in southeast Asia and in central and Eastern Europe, particularly in Siberia and other parts of the former Soviet Union. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10648?source=see_link\">",
"       \"Liver flukes: Clonorchiasis and opisthorchiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fascioliasis is infection caused by one of two liver flukes, either Fasciola hepatica or Fasciola gigantica. F. hepatica is more common and has a worldwide distribution, while F. gigantica occurs predominantly in the tropics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=see_link\">",
"       \"Liver flukes: Fascioliasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ascaris lumbricoides, an intestinal roundworm, has also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. It is one of the most common helminthic human infections worldwide, infecting more than 1.4 billion people or 25 percent of the world's population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the epidemiologic association, evidence supporting the role of these infections in the pathogenesis of OCH is inconclusive. While these infections can be demonstrated in 20 to 45 percent of patients with OCH, they are not uniformly present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/8,11,12,16\">",
"     8,11,12,16",
"    </a>",
"    ]. Furthermore, recurrent pyogenic cholangitis is relatively common in some Asian countries in which these parasites are not endemic. Certain areas of China, Taiwan, and Japan where the recurrent pyogenic cholangitis is relatively common, are virtually free of Clonorchis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two possible explanations may contribute to the variable detection of parasitic infection in patients with OCH. First, the prevalence of infection depends upon the sensitivity of the diagnostic testing being performed; the rigor with which infection was sought was variable among studies. Second, the infection may have resolved after initiating the disease without leaving detectable footprints of the inciting cause. In support of this hypothesis are studies in which the analysis of stones has shown debris and ova, which may have served as a nidus for stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigment stones seen in patients with recurrent pyogenic cholangitis may be caused by the action of bacterial glucuronidases, which produce unconjugated bilirubin from bilirubin glucuronide in the bile ducts. Insoluble calcium bilirubinate stones form when the unconjugated bilirubin complexes with calcium. Once the stones have formed, they may lead to a cycle of persistent obstruction predisposing to stasis and recurrent infection with additional stone formation.",
"   </p>",
"   <p>",
"    The source of entry of bacteria is unclear. Some studies suggest bacteremia from a portal source originating from the lower intestine. Others suggest that the bacteria gain entry to the biliary tree as a result of injury from a parasitic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/15,18-21\">",
"     15,18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is uncertain whether bacterial infection is a cause or the result of the formation of stones, although at least one study suggested that infection followed the formation of stones [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, recurrent bacterial infection in the biliary tree seen in other disorders does not lead invariably to stone formation. One possible explanation may be that patients with recurrent pyogenic cholangitis lack an inhibitor of bacterial glucuronidases present in normal bile [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/10,11,17,23-27\">",
"     10,11,17,23-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, it is generally accepted that stasis, stricturing, and recurrent infection contribute to the pathogenesis of recurrent pyogenic cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/10,28-30\">",
"     10,28-30",
"    </a>",
"    ]. Stricture formation has generally been considered to be a secondary occurrence from the repeated episodes of inflammation and healing. However, it is also possible that stone formation and recurrent infection occur as a result of biliary stricture formation. Animal experiments in which an incomplete stricture was produced around the terminal common bile duct caused formation of stones in the gallbladder and intrahepatic ducts even without evidence of bile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically present with recurrent bouts of cholangitis, characterized by Charcot's triad of right upper quadrant or epigastric pain, fever with or without rigors, and jaundice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .) Other complications related to passage of biliary stones (such as pancreatitis) have also been described. In a study of 41 patients, the most common presenting features were cholangitis (44 percent), abdominal pain without overt cholangitis (32 percent), and pancreatitis (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is established in only 15 to 30 percent of patients after symptoms first develop. Many patients have a history of recurrent symptoms, for which they have not sought medical attention. Repeated attacks can lead to progressive damage to the bile ducts and liver parenchyma, which can result in formation of liver abscesses or cirrhosis.",
"   </p>",
"   <p>",
"    Some patients may have a more fulminant presentation with a variety of complications. The recurrent attacks of cholangitis can lead to sepsis and abscess formation at distant sites, including the lungs and the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Other potential complications include rupture of obstructed pus-filled bile ducts into the peritoneum or formation of a fistula into the gastrointestinal tract or abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/8,11,33\">",
"     8,11,33",
"    </a>",
"    ]. Fistulization can also occur into the pericardium or vascular structures. Portal vein thrombosis and hemobilia have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, patients may be jaundiced. Epigastric and right upper quadrant tenderness and hepatomegaly may be present. Other physical findings reflect the occurrence of the specific complications noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of recurrent pyogenic cholangitis is established by imaging of the liver and biliary system in patients with a clinically compatible history.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A right upper quadrant ultrasound is a useful initial test; ductal dilation and stones can be seen in 85 to 90 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/10,34\">",
"       10,34",
"      </a>",
"      ]. Hepatic abscesses can also be seen.",
"     </li>",
"     <li>",
"      More detailed information can be obtained from a CT scan, which also complements cholangiography since cholangiography may not fully visualize segments of the biliary tree that are obstructed due to stricturing (see below) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]. A variety of CT findings have been described, including dilated central intrahepatic ducts, abrupt tapering of peripheral ducts, enhancement of the duct walls, hepatic abscesses, bilomas, and stones (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55272 \" href=\"UTD.htm?35/36/36416\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/35\">",
"       35",
"      </a>",
"      ]. CT can also demonstrate whether the disease is localized (usually to the left lobe) and whether atrophy has developed. These are important considerations in determining a treatment plan.",
"     </li>",
"     <li>",
"      Cholangiography can be obtained by endoscopic retrograde cholangiopancreatography (ERCP) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67057 \" href=\"UTD.htm?38/61/39903\">",
"       image 2",
"      </a>",
"      ), magnetic resonance cholangiopancreatography (MRCP), or percutaneously (PTC) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. (See appropriate topic reviews.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An advantage of MRCP is that it is non-invasive and can provide detailed visualization of the extent of biliary involvement (which may not always be possible with ERCP or PTC if dye cannot be introduced into extensively strictured or occluded segments). Its major disadvantage compared with ERCP and PTC is that it does not permit therapeutic intervention. PTC is typically reserved for patients in whom biliary imaging cannot be obtained by ERCP or MRCP or in whom therapeutic intervention through the percutaneous tract is planned. Patients undergoing PTC or ERCP should receive prophylactic antibiotics because of the risk of inciting cholangitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis following manipulation of the bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/36,39\">",
"     36,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholangiography may reveal a variety of abnormalities, including intra- and extra- hepatic duct dilatation, straightened intrahepatic ducts with less acute or right-angled branching patterns (as a result of extensive periductal fibrosis), and decreased arborization and acute tapering of the peripheral ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. This produces a classic \"arrowhead\" sign [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. There may be a \"missing duct\" sign where there is complete obstruction of a bile duct.",
"   </p>",
"   <p>",
"    All patients with newly diagnosed recurrent pyogenic cholangitis should have their stools checked for ova and parasites. As a general rule, liver biopsies are not helpful for diagnosing recurrent pyogenic cholangitis or for finding evidence of parasitic infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with recurrent pyogenic cholangitis should involve a multidisciplinary approach since endoscopic, surgical, and radiologic interventions may be required. There are two general considerations in the care of patients: treatment of acute complications such as cholangitis, and long-term prevention of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with complications such as cholangitis should be treated appropriately with fluid resuscitation, antibiotics, and biliary drainage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .) However, in contrast with patients who develop cholangitis as a result of an impacted common bile duct stone, it may be more difficult to achieve drainage in patients with recurrent pyogenic cholangitis since multiple intra- and extrahepatic stones may be present. Stricturing, intrahepatic duct stone impaction, and ductal angulation can add further challenge to endoscopic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Nevertheless, in skilled hands, it may be possible to clear sites of biliary obstruction and achieve adequate drainage until more definitive therapy can be accomplished [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/36,37,43,44\">",
"     36,37,43,44",
"    </a>",
"    ]. Acutely ill patients in whom adequate drainage cannot be achieved during ERCP will require percutaneous or surgical drainage. Surgery often involves cholecystectomy with common bile duct exploration and T-tube drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention of long-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been two general approaches to the prevention of long-term complications in patients with recurrent pyogenic cholangitis. The first involves attempting to remove as many stones as possible with regular surveillance and intervention for stone recurrence. The second involves surgical resection of the affected hepatobiliary segment with a biliary-enteric anastomosis. Optimal strategies have not been well established in large comparative studies. For many patients, a combination of approaches may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clearance of stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of methods for clearing intrahepatic stones has been described, including endoscopic, percutaneous, surgical, and combined techniques. The choice among these should be guided by specific anatomic considerations in individual patients and the availability of local expertise.",
"   </p>",
"   <p>",
"    Stones and infected bile can be removed using a choledochoscope (a small caliber endoscope) passed either percutaneously through the T-tube tract [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/45-47\">",
"     45-47",
"    </a>",
"    ], through a hepaticocutaneous jejunostomy site [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/48\">",
"     48",
"    </a>",
"    ], or via the transpapillary route during ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/49\">",
"     49",
"    </a>",
"    ]. Multiple sessions are usually required. These approaches also permit dilation of intrahepatic strictures, and the fragmentation of stones that are difficult to remove with conventional means with the addition of mechanical, electrohydraulic, or laser lithotripsy (see appropriate topic reviews.)",
"   </p>",
"   <p>",
"    The efficacy of combined approaches was illustrated in a study that focused on 190 of 245 patients in whom surgical choledocholithotomy failed to remove stones completely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients subsequently underwent biliary dilation and stenting, performed through the T-tube tract, and then underwent choledochoscopy and electrohydraulic lithotripsy. Complete stone removal was achieved in 88 percent of these patients. Stone clearance is often difficult to achieve with these techniques in patients with right-sided stone disease and in those with anatomic abnormalities, such as sharp angulation of the biliary tree [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stones recur in more than 30 percent of patients, even in those in whom they can be cleared completely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The rate with which this occurs is variable but is more likely in patients with an intrahepatic duct stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/47\">",
"     47",
"    </a>",
"    ]. As a general rule, most patients should undergo periodic surveillance to monitor for stone recurrence. We usually accomplish this by obtaining serial right upper quadrant ultrasound examinations every three to six months initially, then less often based on clinical indication. Patients who develop recurrent symptoms undergo an ERCP, possibly with therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the risk of stone recurrence can be decreased with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UCDA) or other prophylactic measures (such as courses of antibiotics) is unknown. UDCA will have no significant effect on dissolving existing stones in most patients since they are composed predominantly of calcium bilirubinate, not cholesterol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .) However, case reports have suggested a possible benefit from UDCA in patients in whom analysis of stone composition revealed cholesterol stones [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/53\">",
"     53",
"    </a>",
"    ]. Despite the limited data, we usually add UDCA (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day) because it may increase bile flow, make bile less viscous, and reduce the likelihood of stone formation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodiol",
"    </a>",
"    increases bicarbonate rich bile flow in animal studies, and probably in humans as well [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hepatic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of the hepatobiliary segments that are considered to be the main source of complications may be feasible in the minority of patients in whom the disease is localized (typically in the left hepatic ductal system) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/52,57-65\">",
"     52,57-65",
"    </a>",
"    ] although bilateral partial hepatectomy has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/66\">",
"     66",
"    </a>",
"    ]. The goal of surgery is to resect the area of recurrent infection, biliary stasis, and hepatic atrophy.",
"   </p>",
"   <p>",
"    There have been no large controlled trials comparing hepatic resection with other management strategies. Most studies have been retrospective reports of patients followed in major centers in Asia over many years. As a general rule, these reports have suggested higher rates of residual biliary strictures and more frequent stone recurrence in patients who underwent percutaneous transhepatic cholangioscopic lithotomy without hepatic resection, even with completed stone removal, compared to those who had left lobectomy with a biliary drainage procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Better quality of life, lower rates of secondary biliary cirrhosis, cholangiocarcinoma, and mortality have also been suggested in patients treated surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/52,62,64\">",
"     52,62,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients frequently require a biliary enteric anastomosis (such as a hepaticojejunostomy), although the efficacy and safety of this approach remain controversial. Standard biliary drainage procedures (such as choledochoduodenostomy, Roux-en-Y choledochojejunostomy, or sphincteroplasty) are generally contraindicated since residual strictured biliary segments may not be drained adequately [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/70\">",
"     70",
"    </a>",
"    ]. A few patients have undergone orthotopic liver transplantation for cirrhosis from recurrent pyogenic cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Long-term biliary access has been achieved by creation of a cutaneous stoma from a roux limb of a hepaticojejunostomy in some case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/48,73\">",
"     48,73",
"    </a>",
"    ]. The following examples illustrate the results in some of the largest, English-language surgical series with the longest follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/52,57\">",
"     52,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from Taiwan focused on 380 patients treated surgically and 47 patients treated with percutaneous transhepatic cholangioscopy who were followed for 4 to 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/52\">",
"       52",
"      </a>",
"      ]. The overall rate of recurrent stone formation was 30 percent. A repeated operation was required in 19 percent of patients. Patients treated with hepatectomy were more likely to be symptom free, had a lower rate of stone recurrence and mortality, and were less likely to develop secondary biliary cirrhosis or cholangiocarcinoma.",
"     </li>",
"     <li>",
"      Another series focused on 159 patients who underwent surgical treatment during a 23-year period in Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/57\">",
"       57",
"      </a>",
"      ]. A hepatectomy was performed in 60 percent while 40 percent had liver-preserving surgery by means of intra- and postoperative endoscopic lithotripsy. An hepaticojejunostomy was created in 72 patients (45 percent). Residual stones were present in 30 percent of patients, 30 percent of whom developed recurrent cholangitis. The rate of cholangitis was higher in patients who had undergone a hepaticojejunostomy compared with those who did not undergo a biliary-enteric anastomosis.",
"     </li>",
"     <li>",
"      A third series of 136 patients combined hepatic resection with lithotripsy performed during choledochoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/66\">",
"       66",
"      </a>",
"      ]. A subset of patients (n = 54) underwent bilateral hepatectomy. Immediate stone clearance rates after bilateral and unilateral hepatectomy were 82 and 66 percent, respectively. Hospital mortality rates were 5.6 and 0 percent, while overall complicate rates were 46 and 46 percent, respectively. These observations support the feasibility of partial hepatectomy in patients with bilateral hepatolithiasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of death in patients with recurrent pyogenic cholangitis are sepsis, liver failure, or complications from cirrhosis, such as portal hypertension. Patients are also at increased risk for cholangiocarcinoma. In the study of 427 patients with hepatolithiasis described above [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/52\">",
"     52",
"    </a>",
"    ], 7 percent developed secondary biliary cirrhosis and 3 percent developed cholangiocarcinoma. Overall, disease-related mortality was 10 percent. In another report, cholangiocarcinoma occurred in 55 of 1105 Taiwanese patients (annual incidence of 5 percent) with hepatolithiasis seen during a three-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14472/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholangiocarcinoma should be suspected in patients with clinical deterioration (such as worsening jaundice and weight loss) or with unexplained increases in liver cholestatic measures (such as alkaline phosphatase). Tumors frequently arise in the atrophied left lobe of the liver. The benefit of screening patients for cholangiocarcinoma has not been established. One could consider routinely performing cytology brushings at the time of ERCP, although the yield is disappointingly low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19816?source=see_link\">",
"     \"Endoscopic methods for the diagnosis of pancreatobiliary neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent pyogenic cholangitis is a disease characterized by intrabiliary pigment stone formation, resulting in stricturing of the biliary tree and biliary obstruction with recurrent bouts of cholangitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent pyogenic cholangitis is found almost exclusively in people who live or who have lived in Southeast Asia.",
"     </li>",
"     <li>",
"      The etiology of recurrent pyogenic cholangitis is unknown, although many theories have been proposed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with recurrent bouts of cholangitis, characterized by Charcot's triad of right upper quadrant or epigastric pain, fever with or without rigors, and jaundice. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"       \"Acute cholangitis\"",
"      </a>",
"      .) Other complications related to passage of biliary stones (such as pancreatitis) have been described. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is established by imaging of the liver and biliary system in patients with a clinically compatible history. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with recurrent pyogenic cholangitis should involve a multidisciplinary approach since endoscopic, surgical, and radiologic interventions may be required. There are two general considerations in the care of patients: treatment of acute complications such as cholangitis, and long-term prevention of complications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25634124\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/1\">",
"      Digby K. Common duct stones of liver origin. Br J Sur 1930; 17:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/2\">",
"      Nakayama F, Furusawa T, Nakama T. Hepatolithiasis in Japan: present status. Am J Surg 1980; 139:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/3\">",
"      GLENN F, MOODY FG. Intrahepatic calculi. Ann Surg 1961; 153:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/4\">",
"      Miyake H, Johnston CG. Gallstones: ethnological studies. Digestion 1968; 1:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/5\">",
"      Nakayama F, Soloway RD, Nakama T, et al. Hepatolithiasis in East Asia. Retrospective study. Dig Dis Sci 1986; 31:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/6\">",
"      Ker CG, Huang TJ, Sheen PC. [Intrahepatic stones. 1. Etiological study (author's transl)]. Taiwan Yi Xue Hui Za Zhi 1981; 80:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/7\">",
"      ONG GB. A study of recurrent pyogenic cholangitis. Arch Surg 1962; 84:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/8\">",
"      Carmona RH, Crass RA, Lim RC Jr, Trunkey DD. Oriental cholangitis. Am J Surg 1984; 148:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/9\">",
"      Yellin AE, Donovan AJ. Biliary lithiasis and helminthiasis. Am J Surg 1981; 142:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/10\">",
"      Lim JH. Oriental cholangiohepatitis: pathologic, clinical, and radiologic features. AJR Am J Roentgenol 1991; 157:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/11\">",
"      Chou ST, Chan CW. Recurrent pyogenic cholangitis: a necropsy study. Pathology 1980; 12:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/12\">",
"      Seel DJ, Park YK. Oriental infestational cholangitis. Am J Surg 1983; 146:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/13\">",
"      Shoda J, Inada Y, Osuga T. Molecular pathogenesis of hepatolithiasis--a type of low phospholipid-associated cholelithiasis. Front Biosci 2006; 11:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/14\">",
"      Cosenza CA, Durazo F, Stain SC, et al. Current management of recurrent pyogenic cholangitis. Am Surg 1999; 65:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/15\">",
"      Lim JH. Radiologic findings of clonorchiasis. AJR Am J Roentgenol 1990; 155:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/16\">",
"      Huang MH, Chen CH, Yen CM, et al. Relation of hepatolithiasis to helminthic infestation. J Gastroenterol Hepatol 2005; 20:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/17\">",
"      Nakayama F, Koga A. Hepatolithiasis: present status. World J Surg 1984; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/18\">",
"      Nagase M, Tanimura H, Setoyama M, Hikasa Y. Present features of gallstones in Japan. A collective review of 2,144 cases. Am J Surg 1978; 135:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/19\">",
"      MAKI T. Cholelithiasis in the Japanese. Arch Surg 1961; 82:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/20\">",
"      Bain VG, Ardao GH, Kowalewska-Grochowska K, et al. Biliary ascariasis. J Clin Gastroenterol 1988; 10:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/21\">",
"      Schulman A. Non-western patterns of biliary stones and the role of ascariasis. Radiology 1987; 162:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/22\">",
"      Cetta FM. Bile infection documented as initial event in the pathogenesis of brown pigment biliary stones. Hepatology 1986; 6:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/23\">",
"      Spivak W, DiVenuto D, Yuey W. Non-enzymic hydrolysis of bilirubin mono- and diglucuronide to unconjugated bilirubin in model and native bile systems. Potential role in the formation of gallstones. Biochem J 1987; 242:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/24\">",
"      MATSUSHIRO T. IDENTIFICATION OF GLUCARO-1,4-LACTONE IN BILE AS A FACTOR RESPONSIBLE FOR INHIBITORY EFFECT OF BILE ON BACTERIAL BETA-GLUCURONIDASE. Tohoku J Exp Med 1965; 85:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/25\">",
"      Ostrow JD. The etiology of pigment gallstones. Hepatology 1984; 4:215S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/26\">",
"      Matsushiro T, Suzuki N, Sato T, Maki T. Effects of diet on glucaric acid concentration in bile and the formation of calcium bilirubinate gallstones. Gastroenterology 1977; 72:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/27\">",
"      Hikasa Y, Nagase M, Tanimura H, et al. Epidemiology and eti&oacute;logy of gallstones. Nihon Geka Hokan 1980; 49:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/28\">",
"      Matsumoto Y, Fujii H, Yoshioka M, et al. Biliary strictures as a cause of primary intrahepatic bile duct stones. World J Surg 1986; 10:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/29\">",
"      Lindel&ouml;f G, Van der Linden W. The role of stasis in experimental gallstone formation. Acta Chir Scand 1965; 130:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/30\">",
"      Trotman BW, Soloway RD. Pigment gallstone disease: Summary of the National Institutes of Health--international workshop. Hepatology 1982; 2:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/31\">",
"      IMAMOGLU K, PERRY JF Jr, WANGENSTEEN OH. [Experimental production of gallstones by incomplete stricture of the terminal common bile duct]. Surgery 1957; 42:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/32\">",
"      IMAMOGLU K, YONEHIRO EG, PERRY JF Jr, WANGENSTEEN OH. Formation of calculi following cholecystectomy attending partial occlusions of the common bile duct. Surg Forum 1957; 8:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/33\">",
"      Sperling RM, Koch J, Sandhu JS, Cello JP. Recurrent pyogenic cholangitis in Asian immigrants to the United States: natural history and role of therapeutic ERCP. Dig Dis Sci 1997; 42:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/34\">",
"      Lim JH, Ko YT, Lee DH, Hong KS. Oriental cholangiohepatitis: sonographic findings in 48 cases. AJR Am J Roentgenol 1990; 155:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/35\">",
"      Chan FL, Man SW, Leong LL, Fan ST. Evaluation of recurrent pyogenic cholangitis with CT: analysis of 50 patients. Radiology 1989; 170:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/36\">",
"      Choi TK, Wong J. Endoscopic retrograde cholangiopancreatography and endoscopic papillotomy in recurrent pyogenic cholangitis. Clin Gastroenterol 1986; 15:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/37\">",
"      Khuroo MS, Dar MY, Yattoo GN, et al. Serial cholangiographic appearances in recurrent pyogenic cholangitis. Gastrointest Endosc 1993; 39:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/38\">",
"      Safar F, Kamura T, Okamuto K, et al. Magnetic resonance T1 gradient-echo imaging in hepatolithiasis. Abdom Imaging 2005; 30:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/39\">",
"      Lam SK, Wong KP, Chan PK, et al. Recurrent pyogenic cholangitis: a study by endoscopic retrograde cholangiography. Gastroenterology 1978; 74:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/40\">",
"      Kartheuser AH, Dozois RR, Wiesner RH, et al. Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. Ann Surg 1993; 217:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/41\">",
"      Post AB, Bozdech JM, Lavery I, Barnes DS. Colectomy in patients with inflammatory bowel disease and primary sclerosing cholangitis. Dis Colon Rectum 1994; 37:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/42\">",
"      Mahadeva S, Prabakharan R, Goh KL. Endoscopic intervention for hepatolithiasis associated with sharp angulation of right intrahepatic ducts. Gastrointest Endosc 2003; 58:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/43\">",
"      Fan ST, Choi TK, Wong J. Recurrent pyogenic cholangitis: current management. World J Surg 1991; 15:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/44\">",
"      Tanaka M, Ikeda S, Ogawa Y, et al. Divergent effects of endoscopic sphincterotomy on the long-term outcome of hepatolithiasis. Gastrointest Endosc 1996; 43:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/45\">",
"      Yoshida J, Chijiiwa K, Shimizu S, et al. Hepatolithiasis: outcome of cholangioscopic lithotomy and dilation of bile duct stricture. Surgery 1998; 123:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/46\">",
"      Sheen-Chen SM, Chou FF, Lee CM, et al. The management of complicated hepatolithiasis with intrahepatic biliary stricture by the combination of T-tube tract dilation and endoscopic electrohydraulic lithotripsy. Gastrointest Endosc 1993; 39:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/47\">",
"      Chen C, Huang M, Yang J, et al. Reappraisal of percutaneous transhepatic cholangioscopic lithotomy for primary hepatolithiasis. Surg Endosc 2005; 19:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/48\">",
"      Fan ST, Mok F, Zheng SS, et al. Appraisal of hepaticocutaneous jejunostomy in the management of hepatolithiasis. Am J Surg 1993; 165:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/49\">",
"      Okugawa T, Tsuyuguchi T, K C S, et al. Peroral cholangioscopic treatment of hepatolithiasis: Long-term results. Gastrointest Endosc 2002; 56:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/50\">",
"      Gott PE, Tieva MH, Barcia PJ, Laberge JM. Biliary access procedure in the management of oriental cholangiohepatitis. Am Surg 1996; 62:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/51\">",
"      Cheng YF, Lee TY, Sheen-Chen SM, et al. Treatment of complicated hepatolithiasis with intrahepatic biliary stricture by ductal dilatation and stenting: long-term results. World J Surg 2000; 24:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/52\">",
"      Jan YY, Chen MF, Wang CS, et al. Surgical treatment of hepatolithiasis: long-term results. Surgery 1996; 120:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/53\">",
"      Strichartz SD, Abedin MZ, Ippoliti AF, et al. Intrahepatic cholesterol stones: a rationale for dissolution therapy. Gastroenterology 1991; 100:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/54\">",
"      Dumont M, Erlinger S, Uchman S. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport. Gastroenterology 1980; 79:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/55\">",
"      Renner EL, Lake JR, Cragoe EJ Jr, et al. Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors. Am J Physiol 1988; 254:G232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/56\">",
"      Erlinger S. Hypercholeretic bile acids: a clue to the mechanism? Hepatology 1990; 11:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/57\">",
"      Kusano T, Isa TT, Muto Y, et al. Long-term results of hepaticojejunostomy for hepatolithiasis. Am Surg 2001; 67:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/58\">",
"      Sun WB, Han BL, Cai JX. The surgical treatment of isolated left-sided hepatolithiasis: a 22-year experience. Surgery 2000; 127:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/59\">",
"      Stain SC, Incarbone R, Guthrie CR, et al. Surgical treatment of recurrent pyogenic cholangitis. Arch Surg 1995; 130:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/60\">",
"      Choi TK. Intrahepatic stones. Br J Surg 1989; 76:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/61\">",
"      He XD, Liu W, Li BL, et al. Combined surgical therapy for hepatolithiasis. Chin Med Sci J 2005; 20:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/62\">",
"      Cheung MT, Kwok PC. Liver resection for intrahepatic stones. Arch Surg 2005; 140:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/63\">",
"      Li X, Shi L, Wang Y, Tian FZ. Middle and long-term clinical outcomes of patients with regional hepatolithiasis after subcutaneous tunnel and hepatocholangioplasty with utilization of the gallbladder. Hepatobiliary Pancreat Dis Int 2005; 4:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/64\">",
"      Vetrone G, Ercolani G, Grazi GL, et al. Surgical therapy for hepatolithiasis: a Western experience. J Am Coll Surg 2006; 202:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/65\">",
"      Uenishi T, Hamba H, Takemura S, et al. Outcomes of hepatic resection for hepatolithiasis. Am J Surg 2009; 198:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/66\">",
"      Yang T, Lau WY, Lai EC, et al. Hepatectomy for bilateral primary hepatolithiasis: a cohort study. Ann Surg 2010; 251:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/67\">",
"      Yoon HK, Sung KB, Song HY, et al. Benign biliary strictures associated with recurrent pyogenic cholangitis: treatment with expandable metallic stents. AJR Am J Roentgenol 1997; 169:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/68\">",
"      Chijiiwa K, Yamashita H, Yoshida J, et al. Current management and long-term prognosis of hepatolithiasis. Arch Surg 1995; 130:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/69\">",
"      Otani K, Shimizu S, Chijiiwa K, et al. Comparison of treatments for hepatolithiasis: hepatic resection versus cholangioscopic lithotomy. J Am Coll Surg 1999; 189:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/70\">",
"      Yamakawa T, Komaki F, Kitano Y, et al. Intrahepatic stones and postoperative choledochoscopy. Gastroenterol Jpn 1980; 15:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/71\">",
"      Strong RW, Chew SP, Wall DR, et al. Liver transplantation for hepatolithiasis. Asian J Surg 2002; 25:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/72\">",
"      Pan GD, Yan LN, Li B, et al. Liver transplantation for patients with hepatolithiasis. Hepatobiliary Pancreat Dis Int 2005; 4:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/73\">",
"      Saing H, Chan KL, Mya GH, et al. Cutaneous stoma in the roux limb of hepaticojejunostomy (hepaticocutaneous jejunostomy): useful access for intrahepatic stone extraction. J Pediatr Surg 1996; 31:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14472/abstract/74\">",
"      Chen MF, Jan YY, Wang CS, et al. A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer 1993; 71:2461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 652 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14472=[""].join("\n");
var outline_f14_8_14472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Parasitic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention of long-term complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clearance of stones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hepatic resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25634124\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/652|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/36/36416\" title=\"diagnostic image 1\">",
"      Oriental cholangiohepatitis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/61/39903\" title=\"diagnostic image 2\">",
"      Oriental cholangiohep ERCP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=related_link\">",
"      Ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19816?source=related_link\">",
"      Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10648?source=related_link\">",
"      Liver flukes: Clonorchiasis and opisthorchiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=related_link\">",
"      Liver flukes: Fascioliasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_8_14473="Legal aspects of end of life care";
var content_f14_8_14473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Legal aspects of end of life care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14473/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14473/contributors\">",
"     Ezekiel J Emanuel, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14473/contributors\">",
"     Linda Emanuel, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14473/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/8/14473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caring for patients at the end of life is a challenging task that requires not only the consideration of the patient as a whole but also an understanding of the family, social, legal, economic, and institutional circumstances that surround patient care. Unfortunately, there are many myths and misconceptions about what may or may not be ethical and legal in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, fear of litigation may prompt unnecessary interventions or hinder clinicians from acting completely ethically in patients with life-threatening illnesses. One study found that as many as 93 percent of clinicians in high-risk medical specialties (ie, emergency medicine, general surgery, orthopedic surgery, neurosurgery,",
"    <span class=\"nowrap\">",
"     obstetrics/gynecology,",
"    </span>",
"    and radiology) report practicing defensive medicine such that they did testing beyond what they clinically felt was necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/2\">",
"     2",
"    </a>",
"    ]. Understanding the legal aspects of end-of-life care should give the practicing clinician the confidence and freedom to act ethically and reasonably.",
"   </p>",
"   <p>",
"    Legal issues addressed in this section include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cases of legal precedence in the withdrawal of medical care",
"     </li>",
"     <li>",
"      What medical treatments can be stopped?",
"     </li>",
"     <li>",
"      Who can refuse medical treatment?",
"     </li>",
"     <li>",
"      How to determine if a patient has the capacity to make decisions",
"     </li>",
"     <li>",
"      Who should make the decision if the patient is incapacitated?",
"     </li>",
"     <li>",
"      What guidelines are available for surrogates to help make decisions?",
"     </li>",
"     <li>",
"      Communication and documentation in end-of-life care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of the legal standards regarding end-of-life care in the United States vary by state, but there are specific legal precedents surrounding end-of-life care that generalize. When in doubt, clinicians should consider an ethics consultation, seek legal counsel, or seek assistance from risk management.",
"   </p>",
"   <p>",
"    This topic review will discuss issues related to legal aspects of end-of-life care that are specific to the United States. These may not apply to outside of the United States although many of the principles are becoming more widely accepted.",
"   </p>",
"   <p>",
"    Ethical issues regarding end-of-life care, euthanasia and physician assisted suicide, ethics in the intensive care unit, and the effect of religion and spirituality on end-of-life care are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=see_link\">",
"     \"Ethics in the intensive care unit: Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WITHDRAWAL OF MEDICAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Historic perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout the history of medicine, a primary responsibility for clinicians has been the care of dying patients. Over centuries, clinicians have developed ethical norms regarding care of the dying including the withdrawal and withholding of life-sustaining treatments.",
"   </p>",
"   <p>",
"    The first suggestion that clinicians should withhold medical interventions from terminally ill patients in some circumstances probably dates to Hippocrates' injunction \"to refuse to treat those (patients) who are overmastered by their disease, realizing that in such cases medicine is powerless\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, clinicians and religious leaders also have argued that withholding care from dying patients may be appropriate in some situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1835, Jacob Bigelow urged fellow members of the Massachusetts Medical Society to withhold \"therapies\", such as cathartics and emetics, from hopelessly ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1848, John Warren, the surgeon who performed the first operation with ether anesthesia, urged that ether should be used \"in mitigating the agonies of death\" [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1958, Pope Pius XII, in response to questions about resuscitating patients and maintaining comatose patients on respirators, stated that clinicians had no obligation to use such \"extraordinary\" means to forestall death [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The right to refuse medical interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to 1976, legal cases in the United States involving the refusal of life-sustaining medical care usually involved Jehovah's Witnesses. These decisions were justified based upon the First Amendment's right of religious freedom.",
"   </p>",
"   <p>",
"    In 1975, this changed with the Quinlan case. In that case, 21-year-old Karen Ann Quinlan suffered two 15-minute long apneic periods probably related to intoxication with alcohol and drugs. While her friends had attempted resuscitation, she was comatose when she arrived at the hospital and, one year later, was in a persistent vegetative state requiring respiratory support and artificial feedings. After consulting with his priest, Quinlan's father wanted her to be taken off the ventilator. Initially, his request was denied. The New Jersey Supreme Court ruled that the right to privacy includes a right to refuse medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/7\">",
"     7",
"    </a>",
"    ]; this right extends to incompetent patients, and the right can be exercised on their behalf by their legal guardian. Importantly, the Court argued that decisions to withdraw medical treatments did not require going to court but could be handled by hospital ethics committees, clinicians, and families.",
"   </p>",
"   <p>",
"    Karen Ann Quinlan was taken off the ventilator and was able to breathe on her own. She was kept alive for nine more years with artificial nutrition and hydration.",
"   </p>",
"   <p>",
"    The Quinlan case changed the focus in cases of treatment refusal from a right of religious freedom to a person's so-called \"right to die\". Throughout the last part of the 1970s and 1980s, many state courts, particularly in California, Florida, Massachusetts, and New Jersey, established the legal norms for terminating life-sustaining treatment. Nearly 15 years of rulings at the state level were solidified when the US Supreme Court decided the Cruzan case in 1990, a case that is very similar to the Quinlan case.",
"   </p>",
"   <p>",
"    Nancy Beth Cruzan was 31-years-old when she was in an automobile accident; this resulted in severe brain damage that placed her in a persistent vegetative state, dependent upon a feeding tube. After four years without improvement in her cognitive function, her family asked to have her artificial feeding and hydration stopped. In its decision, the United States Supreme Court recognized that competent patients have a constitutional right to refuse medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8\">",
"     8",
"    </a>",
"    ]. Using the Fifth Amendment's guarantee that no person shall \"be deprive of life, liberty, or property, without due process of law\" the Supreme Court affirmed patients' rights to refuse medical treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8\">",
"     8",
"    </a>",
"    ]. The Court declared that artificial hydration or nutrition is no different from other medical interventions. Although mentally incapacitated patients have the same right, the Supreme Court allowed states to impose restrictions on how explicit and specific the patient's prior wishes had to be [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After this court ruling, some of Cruzan's friends provided evidence that she had previously expressed wishes that she would want artificial feedings discontinued in such a scenario. As a result of this testimony, her feedings were terminated.",
"   </p>",
"   <p>",
"    Mentally competent patients need not be terminally ill to exercise this right to refuse interventions; they have the right regardless of health status. In addition, the right applies equally to withholding proposed treatments and to discontinuing initiated treatments. Of note, this right to refuse medical care does not imply a correlative right to demand treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1990, 27-year-old Theresa Marie \"Terri\" Schiavo suffered cardiopulmonary arrest in her home leading to a persistent vegetative state requiring artificial nutrition and hydration by feeding tube. After eight years without neurologic recovery, her husband and guardian requested that her feeding tube be removed, but her parents objected and the case went to court. The judge determined that there was \"clear and convincing evidence\" that she would not have wanted to be kept alive in this state. Despite several attempts on the part of Schiavo's parents' to prevent removal of her feeding tube, including claims that she could recover, the Florida state Supreme Court affirmed that her husband could exercise her right and discontinue treatments. The US Supreme Court stood by the lower court's decision and refused to hear the case.",
"   </p>",
"   <p>",
"    This consistent refusal to intervene on behalf of Schiavo's parents' desire to continue nutrition and hydration is reaffirmation of the right to refuse medical care even for mentally incapacitated patients and that artificial nutrition and hydration are medical treatments.",
"   </p>",
"   <p>",
"    The Cruzan case established a constitutionally protected liberty interest in refusing medical treatment, which has been referenced in recent Appellate Court decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/11\">",
"     11",
"    </a>",
"    ]. In theory, as noted by the Cruzan case, the right of patients to refuse medical therapy can be limited by four countervailing state interests in [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preservation of life",
"     </li>",
"     <li>",
"      Prevention of suicide",
"     </li>",
"     <li>",
"      Protection of third parties such as children",
"     </li>",
"     <li>",
"      Preserving the integrity of the medical profession",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In practice, these interests almost never override the right of competent patients and incompetent terminally ill patients who have left explicit advance directives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192990306\">",
"    <span class=\"h2\">",
"     Physician-assisted suicide and its relationship to withholding treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physician-assisted suicide (PAS) refers to the physician's act of providing medication, a prescription, information, or other interventions to a patient with the understanding that the patient intends to use them to commit suicide. PAS is legal in the Netherlands, Belgium, and Switzerland. In the United States, Oregon legalized PAS in 1997, and the practice was legalized in Washington State in March of 2009. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=see_link&amp;anchor=H2#H2\">",
"     \"Euthanasia and physician assisted suicide\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the 1997 case Washington v. Glucksberg, several physicians counseling patients at the end of life challenged a state law banning PAS on the grounds that the Constitution guarantees the liberty of a consenting, terminally ill adult to commit PAS. The Supreme Court ruled that a state could ban PAS, because such a ban is &ldquo;rationally related to a legitimate government interest&rdquo;, namely preserving human life and upholding the integrity and ethics of the medical profession. Thus, the Court held that individuals do not have a constitutional right to PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, in the 1997 case Vacco v. Quill, the Court maintained that there is a rational basis for a distinction between laws allowing doctors to withhold medical treatment, and laws permitting PAS. As stated by the decision, &ldquo;The law has long used actors' intent or purpose to distinguish between two acts that may have the same result&hellip;a physician who withdraws, or honors a patient's refusal to begin, life-sustaining medical treatment purposefully intends or may so intend, only to respect his patient's wishes&hellip;A doctor who assists a suicide, however, &lsquo;must, necessarily and indubitably, intend primarily that the patient be made dead&rsquo;&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the Court has not held that individuals have a constitutional right to PAS, it has not overturned state laws allowing this practice. In the 2006 case Gonzales v. Oregon, the Supreme Court held 6-3 in favor of preserving Oregon&rsquo;s Death With Dignity Act (ODWDA), which was passed in 1994, and as described by the court, &ldquo;exempts from civil or criminal liability state-licensed physicians who, in compliance with ODWDA's specific safeguards, dispense or prescribe a lethal dose of drugs requested by an Oregon resident with a terminal illness that, within reasonable medical judgment, will cause death within six months&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/14\">",
"     14",
"    </a>",
"    ]. In 2001, the Attorney General had issued an interpretive rule announcing that assisting suicide was not a legitimate medical purpose under Federal drug control legislation, and the Supreme Court upheld an Appellate Court decision that had rejected this interpretation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Medical interventions that can be stopped",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every medical intervention, including artificial nutrition and hydration, may be terminated at the patient's request. Specific legal cases have sanctioned the withholding or withdrawal of respirators, chemotherapy, blood transfusions, hemodialysis, and major surgical operations. In Cruzan, the United States Supreme Court definitively stated that artificial nutrition and hydration are medical interventions that can be withheld or withdrawn under the guidelines that apply to other medical treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessing decision-making capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Competent patients have the exclusive right to refuse medical care. Even in cases where the patient's wishes may conflict with those of his or her family, the patient's right to refuse care is determinative. For mentally incapacitated patients who left living wills or other advance care documents, the wishes in these directives are also definitive.",
"   </p>",
"   <p>",
"    Decisions become more difficult when patients have some cognitive impairment, such as moderate Alzheimer disease. In this situation, the first step is trying to determine if the patient is able to make decisions for him or herself. If not, the next step would be to determine whether they made any previous instructions for their care.",
"   </p>",
"   <p>",
"    Competence must be determined by a judge and relates to whether individuals have the legal right to make their own decisions and whether others should respect the decisions they make. Capacity is the clinical cousin to the legal term competence and is task specific.",
"   </p>",
"   <p>",
"    A patient may have the capacity to express their values and preferences and make decisions regarding treatment even if they are unable to carry out other functions of higher reasoning such as balancing their checkbook or living independently. On the other hand, a patient without capacity may seem intact in superficial conversation but be unable to make decisions regarding their medical care on their own preferences and values. Capacity does not require a formal legal determination or psychiatric evaluation but can be done by clinicians.",
"   </p>",
"   <p>",
"    The following is one method for determining medical capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/15\">",
"     15",
"    </a>",
"    ]: Assess the patient's ability to reason and deliberate about treatments and their consequences. The patient should be able to express their goals and values and explain their choices by reference to these values and goals. Sometimes a patient is unable to give reasoning for his or her decision; this makes it difficult to consider the patient fully capacitated. In addition, the patient should be acting like him or herself. That is, the decision should not be widely \"out-of-character\". There may be good reasons for a complete \"change of heart\" but at least preliminarily consistency with past preferences is a reasonable test. If a patient is not able to fulfill these requirements, there is a question about his or her capacity to make health care decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surrogate decision makers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2010 study of adults age 60 or older who died between 2000 and 2006 found that 42 percent required decision making about treatment in the final days of life, but 70 percent lacked decision-making capacity. Of those lacking decision-making capacity, around one-third did not have advance planning directives [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical practice relies on surrogates to make or help make treatment decisions for incapacitated adults. All states permit a patient-identified agent (durable power of attorney for health care, medical power of attorney, health care agent, or authorized surrogate) or a legal guardian to make decisions about life-sustaining treatment for an incapacitated person. In 12 states, proxies are limited in what decisions they can make by the patient&rsquo;s medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a patient does not have the mental capacity to make medical decisions, a surrogate decision maker should be identified. Frequently, however, surrogates are not formally appointed, and relatives are used in the following order (precise order can vary by state) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spouse",
"     </li>",
"     <li>",
"      Adult child or a majority of the adult children reasonably available",
"     </li>",
"     <li>",
"      Parents of the patient",
"     </li>",
"     <li>",
"      Siblings of the patient",
"     </li>",
"     <li>",
"      Nearest living relative of the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many have maintained that the incapacitated patient's family is the most appropriate surrogate decision maker. In the 1980s, many courts affirmed this view, recognizing that when patients had explicit but unrecorded conversations with family, friends, and others about their wishes regarding terminating treatments, these conversations should be used as decision-making guides.",
"   </p>",
"   <p>",
"    However, empirical studies suggest that spouses and other family members generally do not know the preferences of patients regarding the termination of life-sustaining treatments; therefore, they may not reach the same decision that the patient would have reached [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. One study found that even though patients believed both their family (87 percent) and doctors (90 percent) could accurately represent their wishes, neither family members nor doctors were able to adequately predict patient wishes on scenario testing with agreement ranging from 59 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/22\">",
"     22",
"    </a>",
"    ]. Another investigation found that &ldquo;shared decision making about end-of life treatment choices was often incomplete, especially among less educated families&rdquo; but noted that &ldquo;higher levels of shared decision making were associated with greater family satisfaction&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/23\">",
"     23",
"    </a>",
"    ]. A review of the literature suggests that over one-third of surrogates have a significant prolonged negative psychological experience in making an end of life decision for a family member [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/24\">",
"     24",
"    </a>",
"    ]. A small minority has a positive emotional response, which was significantly correlated with being confident that they know which treatment the patient would have wanted. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    These discrepancies emphasize the importance of",
"    <span class=\"nowrap\">",
"     patient/surrogate",
"    </span>",
"    discussions about preference prior to a loss of capacity. Unfortunately, these proactive discussions are rare and clinicians are usually left relying on the family for decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H2#H2\">",
"     \"Ethical issues near the end of life\", section on 'Who makes the decisions?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Family decisions in court",
"    </span>",
"    &nbsp;&mdash;&nbsp;With Cruzan, the US Supreme Court held that there is no constitutional requirement that families be permitted to exercise the right of mentally incapacitated patients to terminate care when the patients have not left explicit statements of their preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8\">",
"     8",
"    </a>",
"    ]. Importantly, however, the Court did not delineate uniform national rules regarding who should decide for mentally incapacitated patients. Instead, the Court permitted each state to make the rules it deemed best. The Court also endorsed, as legally acceptable but not required, Missouri's contention that the \"evidence of the incompetent's wishes as to the withdrawal of treatment be provided by clear and convincing evidence\".",
"   </p>",
"   <p>",
"    Since then, several state supreme courts have limited the rights of families to decide for incompetent patients when there is no advance care directive or formal appointment of a proxy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. These courts have accepted that, when a patient who is mentally incapacitated is in a persistent vegetative state, comatose, or terminally ill, family members (even if not formally appointed as proxy decision makers) can withdraw life-sustaining treatments based on prior conversations with the patient or their understanding of the patient's values. However, these courts have refused to permit families not formally appointed as proxies to terminate life-sustaining treatments from mentally incapacitated but conscious patients, patients who can interact minimally [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/25\">",
"     25",
"    </a>",
"    ]. Explicit statements by the patient that relate to not wanting to be on life support or in a vegetative state, courts have argued, do not meet the standard of \"clear and convincing\" evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Appellate Court in the Schiavo case, for example, noted that &ldquo;Cruzan did not establish that the Constitution requires application of a clear and convincing evidence standard before termination of care. The Supreme Court held only that a state could, if it wished, require that evidence of the incompetent's wishes be proven by clear and convincing evidence&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These limits emphasize the value of having patients complete formal advance care directives, specifying their wishes regarding life-sustaining treatments and who they want to be their proxy decision maker. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Advance directives'",
"    </a>",
"    below.) Advance directives have been associated with improved quality of care and better communication with bereaved family members [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One problem that seems to be arising with increasing frequency is that families want patients who are comatose, in a persistent vegetative state, or anencephalic maintained with life-sustaining treatments, although the treating clinicians object to providing such care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/30\">",
"     30",
"    </a>",
"    ]. In the Wanglie case, for instance, the family of an elderly woman in a persistent vegetative state wanted her respirator continued. The court ruled that the family had a right to decide what treatments the patient should receive.",
"   </p>",
"   <p>",
"    Families have sued when advance directives or family preferences are ignored. In 2007, a Florida jury awarded $150,000 against a nursing home for keeping a resident on life support for six days against the statements contained in her advance directive. The jury found that the nursing home had failed to develop a plan for managing her care consistent with her living will [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Methods for making decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Competent patients have the right to refuse medical care and can use whatever criteria they deem acceptable; it is their values, whatever they are, that guide their choice [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/32\">",
"     32",
"    </a>",
"    ]. Similarly, for mentally incapacitated patients who left advance directives that specify the interventions they want or do not want, their values determine their choices.",
"   </p>",
"   <p>",
"    Regarding mentally incapacitated patients who either appointed a proxy without specific indications of their wishes or who never completed an advance care directive, this question remains controversial.",
"   </p>",
"   <p>",
"    The following four criteria have been proposed to help guide surrogate decision makers although none of these is ideal:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Ordinary/extraordinary",
"      </span>",
"      care distinction",
"     </li>",
"     <li>",
"      Futile care",
"     </li>",
"     <li>",
"      Substituted judgment",
"     </li>",
"     <li>",
"      Best interests",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ordinary and extraordinary care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the Pope and Catholic teachings, some advocate a distinction between ordinary and extraordinary care, with ordinary care being mandatory, whereas extraordinary care may be withheld or withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/6\">",
"     6",
"    </a>",
"    ]. One commentator explicated this distinction in the following way [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    \"Ordinary means of preserving life are all medicines, treatments, and operations, which offer a reasonable hope of benefit for the patient and which can be obtained and used without excessive expense, pain, or inconvenience. Extraordinary means of preserving life mean all medicines, treatments, and operations, which cannot be obtained without excessive expense, pain, or other inconvenience, or which, if used, would not offer reasonable hope of benefit.\"",
"   </p>",
"   <p>",
"    Nevertheless, many ethicists and courts have concluded that the distinction between ordinary and extraordinary care is too vague and has \"too many conflicting meanings\" to be helpful in guiding surrogate decision makers and clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/9,10,34,35\">",
"     9,10,34,35",
"    </a>",
"    ]. As one lawyer noted, ordinary and extraordinary are \"extremely fact-sensitive, relative terms: what is ordinary for one patient under particular circumstances may be extraordinary for the same patient under different circumstances, or for a different patient under the same circumstances\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, the",
"    <span class=\"nowrap\">",
"     ordinary/extraordinary",
"    </span>",
"    distinction should not be used to justify decisions about stopping treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Futile treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the late 1980s and early 1990s, some argued that clinicians could terminate futile treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/36\">",
"     36",
"    </a>",
"    ]. Unfortunately, the term futility has been used inconsistently [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic futility means that an intervention will have no physiologic effect.",
"     </li>",
"     <li>",
"      Qualitative futility refers to an intervention that \"fails to end a patient's total dependence on intensive medical care\" [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Quantitative futility occurs \"when physicians conclude (either through personal experience, experiences shared with colleagues, or consideration of reported empiric data) that in the last 100 cases, a medical treatment has been useless\" [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, it is now agreed that there is no objective standard of futility; the term merely conceals subjective value judgments about when a treatment is \"not beneficial\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. A recent review of the literature regarding the role of medical futility determinations during end-of-life care stated, &ldquo;The concept of medical futility remains controversial, and there is no general professional consensus about the appropriate use of futility in medical decision making&hellip;&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some hospitals have enacted \"unilateral DNR\" policies to allow clinicians to provide a do-not-resuscitate order in cases where consensus cannot be reached with families and there is medical opinion that resuscitation would be futile if attempted. Many states including, Texas, Virginia, Maryland, and California, have enacted so-called medical futility laws [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/42\">",
"     42",
"    </a>",
"    ]. These laws protect clinicians from liability if they terminate life-sustaining treatments against family wishes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24934?source=see_link\">",
"     \"Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In Texas, if the medical team and family continue to disagree about terminating interventions despite an ethics consultation, then the hospital is supposed to try to facilitate transfer of the patient to another institution willing to provide treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/42\">",
"     42",
"    </a>",
"    ]. If this fails after 10 days, then the hospital and clinician may unilaterally withdraw treatments determined to be futile. The family may appeal to a state court. Early data suggest the law increases futility consultations for the ethics committee and most families concur with withdrawal decision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/42\">",
"     42",
"    </a>",
"    ]. As of 2007, according to data from Baylor University Medical Center on 16 Texas hospitals, there had been 974 ethics committee consultations on medical futility cases, and 65 in which committees ruled against families and gave notice that treatment would be terminated. Treatment was withdrawn for 27 of those patients, while the remainder were transferred to other facilities or died while awaiting transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Substituted judgment",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to court decisions, substituted judgment criterion holds that the surrogate should try to imagine what the patient would do if the patient were competent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/34\">",
"     34",
"    </a>",
"    ]. That is, the proxy should try to \"ascertain the incompetent person's actual interests and preferences\" making a decision which \"would be made by the incompetent person, if that person were competent\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/44\">",
"     44",
"    </a>",
"    ]. The decision is subjective in the sense that the proxy tries to figure out what the incompetent person would want.",
"   </p>",
"   <p>",
"    It may be possible to imagine what the incompetent would want if he or she had left explicit instructions, such as a living will. However, in this case there is no substituted judgment, only carrying out the patient's explicit wishes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/10\">",
"     10",
"    </a>",
"    ]. When there are no explicit instructions, the attempt to predict what the person would want is unrealistic. Unfortunately, most surrogates, even close family members, cannot accurately predict what the patient would have wanted [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Empirical studies suggest that the preferences of individuals regarding medical treatment may shift over time, meaning that surrogates could inaccurately represent a patient&rsquo;s wishes at the time of incapacitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, in the absence of specific guidance from the patient when competent, substituted judgment becomes more of a guessing game or, as some courts have called it, a \"cruel charade\" or \"a legal fiction at best\", than a way of fulfilling the patient's wishes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/10,46\">",
"     10,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Best interests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best-interests criterions holds that the surrogate should evaluate treatments by balancing the benefits and risks and select those treatments in which the benefits maximally outweigh the burdens of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/9,10,47\">",
"     9,10,47",
"    </a>",
"    ]. Legally, this standard is considered \"objective\" because it does not rely on imagining what the patient would choose but rather on some externally defined standard [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/9\">",
"     9",
"    </a>",
"    ]. The President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research endorsed this standard, as have several prominent courts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/9,48\">",
"     9,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the best interests standard to work, there must be some \"objective, societally shared criteria\" about what constitutes benefits and burdens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/48\">",
"     48",
"    </a>",
"    ]. However, as many court cases in which there is conflict between family members or between family members and the medical team (eg, Schiavo and Wanglie cases) make clear, there is no objective way of determining benefits and burdens and how they should be balanced.",
"   </p>",
"   <p>",
"    One court suggested that burden should be determined solely by levels of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/9\">",
"     9",
"    </a>",
"    ]. However, for many people being in a persistent vegetative state, even if they are not feeling pain, is a serious burden they want to avoid. As one dissenting judge put it: \"A decision to focus exclusively on pain as the single criterion ignores and devalues other important ideals regarding life and death\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, deciding what constitutes a benefit or burden seems to depend on a patient's personal values. The notion of an objective best interests standard also seems illusory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192990500\">",
"    <span class=\"h2\">",
"     Position of the US conference of Catholic bishops",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a legal ruling, statements by the US Conference of Catholic Bishops have clarified their position on circumstances under which medical assistance at the end of life could be withdrawn, explaining in 2009, &ldquo;medically assisted nutrition and hydration become morally optional when they cannot reasonably be expected to prolong life or when they would be excessively burdensome for the patient or (would) cause significant physical discomfort, for example resulting from complications in the use of the means employed. For instance, as a patient draws close to inevitable death from an underlying progressive and fatal condition, certain measures to provide nutrition and hydration may become excessively burdensome and therefore not obligatory in light of their very limited ability to prolong life or provide comfort&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192990527\">",
"    <span class=\"h2\">",
"     Addressing difficult cases in end-of-life care",
"    </span>",
"    &nbsp;&mdash;&nbsp;With Cruzan, the US Supreme Court avoided discussing what criteria should help guide surrogate decision makers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8\">",
"     8",
"    </a>",
"    ]. As a matter of practice, clinicians rely on family members to make decisions that they feel is best and only object if these decisions seem to demand treatments that the clinicians consider non-beneficial. Without a perfect solution to the problems raised by proxy decision-making, this approach may be the most reasonable one in difficult circumstances.",
"   </p>",
"   <p>",
"    Surrogates can be influenced by the tone of voice, gestures, and statistical framing of information. As an example, one study showed that a patient is more likely to agree to a procedure that is \"99 percent safe\" than one that had a \"risk of 1 in 100\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/50\">",
"     50",
"    </a>",
"    ]. Since patients often interpret the same information presented as success rates or failure rates differently, it is best to present both points of view. Surrogates must also be cautious of letting their own opinions about what they would like to have done to themselves in a circumstance prejudice their answers.",
"   </p>",
"   <p>",
"    In difficult cases, clinicians, nurses and other care providers should come to an agreement on how they think it is best to care for the patient and whether withdrawal of medical interventions is appropriate. This will typically use the best interest standard informed by whatever knowledge the team has of the patient's previous wishes. This shared understanding among the caregiving team is critical; any dissention makes it harder to approach the family and will frequently become a focus of discussion with the family. Once an agreed upon approach is developed, there should be a discussion with the family to present the reasons why the recommended approach is considered best.",
"   </p>",
"   <p>",
"    When discussing the situation with the family, it is frequently helpful to acknowledge their distress but also to emphasize that the decision is about what is best for the patient and what the patient would want, not what the family members want for themselves. Distinguishing the patient's from the family members' interests can be very helpful. While this approach usually is effective, there is no guarantee. Unfortunately, every clinician will confront a few very difficult seeming irresolvable cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADVANCE DIRECTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is an overview of advance directives. Specific details are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H5#H5\">",
"     \"Ethical issues near the end of life\", section on 'Advance care planning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several instruments for health care planning including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Health care proxy",
"     </li>",
"     <li>",
"      Living will",
"     </li>",
"     <li>",
"      Instructional directive",
"     </li>",
"     <li>",
"      Values history",
"     </li>",
"     <li>",
"      Combined directive",
"     </li>",
"     <li>",
"      Physician Orders for Life-Sustaining Treatment (POLST) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H5#H5\">",
"       \"Ethical issues near the end of life\", section on 'Advance care planning'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are specific limitations and idiosyncrasies with each of these instruments.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 26 states, the living will is not valid if a woman is pregnant because it might harm her unborn baby (",
"      <a class=\"graphic graphic_table graphicRef57771 \" href=\"UTD.htm?27/18/27947\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Because the US Supreme Court recognized a constitutional right to refuse medical treatment, a person does not have to use a state specific form to exercise that right as long as his or her wishes are clear [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many states permit clear and explicit verbal statements to be legally binding directives even if not written down [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/1\">",
"       1",
"      </a>",
"      ]. However, many state courts have refused to extend this to patients who are mentally incompetent but still conscious.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This last issue is illustrated by the Wendland case [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/25\">",
"     25",
"    </a>",
"    ]. A 42-year-old man suffered permanent brain damage and hemiparesis in a car accident [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/25\">",
"     25",
"    </a>",
"    ]. In accord with what they believed were his clear wishes, his family requested that his tube feedings be discontinued. Wendland was not in a persistent vegetative state; he was conscious, able to draw shapes, and follow very simple commands such as choosing a color block. A few months prior to his accident, he had explicitly stated that he would not want to live like his father-in-law who was dying of gangrene and had his ventilator withdrawn at the family's request. Similarly, he explicitly stated to his brother just days before his accident that his brother should not let him be kept alive in a vegetative state. The California Supreme Court ruled that when the patient is conscious and not terminally ill and there is no advance care directive there must be \"clear and convincing\" evidence of the patient's view [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/25\">",
"     25",
"    </a>",
"    ]. According to the court, \"clear and convincing\" evidence requires prior comments to refer to the specific intervention in the specific circumstances of the patient, not a similar or vaguely characterized health state. The family was not permitted to have the feeding tube withdrawn.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least 12 states have limited the authority of proxies to make decisions for certain medical conditions by law [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some states, orally appointed proxies are limited to a particular hospitalization or episode of illness.",
"     </li>",
"     <li>",
"      Several states have put into practice a &ldquo;Physician Orders for Life-Sustaining Treatment (POLST)&rdquo; paradigm, which builds on communication between providers and patients to combine guidance for end-of-life care into a color-coordinated form that follows the patient across treatment settings [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H5#H5\">",
"       \"Ethical issues near the end of life\", section on 'Advance care planning'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, it appears that any properly filled out formal advance care document or durable power of attorney designation, whether it conforms to a state's specific document or not, is protected by the United States Constitution and must be honored [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EUTHANASIA AND PHYSICIAN ASSISTED SUICIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizing on the broad recognition of a right to refuse medical care, some have advocated broadening the right to include euthanasia and PAS. In June 1997, the US Supreme Court ruled unanimously that there is no constitutional right to euthanasia or PAS. The majority view, written by Chief Justice Rehnquist, drew a distinction between the right to withdraw or withhold life-sustaining treatments as a liberty interest in being free of unwanted bodily invasion versus the right to PAS, which does not contain a liberty interest [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. While the Court has not held that individuals have a constitutional right to PAS, it has not overturned state laws allowing this practice. In the 2006 case Gonzales v. Oregon, the Supreme Court held 6-3 in favor of preserving Oregon&rsquo;s Death With Dignity Act (ODWDA), which was passed in 1994, and as described by the court, &ldquo;exempts from civil or criminal liability state-licensed physicians who, in compliance with ODWDA's specific safeguards, dispense or prescribe a lethal dose of drugs requested by an Oregon resident with a terminal illness that, within reasonable medical judgment, will cause death within six months&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/14\">",
"     14",
"    </a>",
"    ]. In 2001, the Attorney General had issued an interpretive rule announcing that assisting suicide was not a legitimate medical purpose under Federal drug control legislation, and the Supreme Court upheld an Appellate Court decision that had rejected this interpretation. Euthanasia and physician assisted suicide are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMMUNICATION AND DOCUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No matter how detailed a physician's knowledge of the law is, physician-patient or physician-family communication is essential for",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    satisfaction with medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. An open dialogue should be encouraged. This is especially important in end-of-life care when many treatment decisions are made based upon patient preferences.",
"   </p>",
"   <p>",
"    Summaries of these interactions should be included in the medical record as they both relate to decisions about current care and can potentially help in future care decisions. Key components of this documentation include who participated in the meeting, how they are related to the patient, and the patient's competency if",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    participates in the discussion along with decisions that were made. Documentation of physician-patient discussions about patient wishes while the patient is still able to express them can help once the patient is no longer mentally competent. Along with medical facts such as physical exam and laboratory values, clinician decision-making and the reasons behind the decisions should be incorporated into the medical record.",
"   </p>",
"   <p>",
"    Goals of treatment are not limited to the promotion of health and prevention of disease, cure, or prevention of untimely death. They can also include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14473/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Education and counseling about the condition and its prognosis",
"     </li>",
"     <li>",
"      Improvement or maintenance of functional status",
"     </li>",
"     <li>",
"      Relief of symptoms, pain, and suffering",
"     </li>",
"     <li>",
"      Emotional support of the patient and family",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specifically mentioning goals of care and which treatments will be given or withheld based on patient preferences clarifies the decision-making process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12938?source=see_link\">",
"     \"Communication in the ICU: Holding a family meeting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       \"Patient information: Sudden cardiac arrest (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laws regarding end-of-life care in the United States vary by state. When in doubt, physicians should seek legal counsel and assistance from their ethics committees for help with individual cases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients must give their explicit consent for care except in specific instances of implied consent. Patients can refuse medical care even if this refusal results in their death. This is based on their constitutional right to be free of bodily invasion without their consent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Withdrawal of medical care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All medical interventions, including artificial nutrition and hydration, may be terminated at the patient's request. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Medical interventions that can be stopped'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To have the capacity to make decisions, the patient must be able to express",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      goals and values and justify",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      choice in association with these values and goals. If a patient does not have the capacity to make medical decisions for",
"      <span class=\"nowrap\">",
"       him/herself,",
"      </span>",
"      a surrogate decision maker should be found. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessing decision-making capacity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Surrogate decision makers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with the capacity to make medical decisions have the exclusive right to refuse medical care even if their wishes conflict with those of their family members. For mentally incapacitated patients who left advanced directives, the wishes in these directives are determinative. Decisions become more difficult when patients are mentally incapacitated but did not previously give instructions for care. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Methods for making decisions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patient who is mentally incapacitated is in a persistent vegetative state, comatose, or terminally ill, family members, even if not formally appointed as proxy decision makers, can withdraw life-sustaining treatments based on prior conversations with the patient or their understanding of the patient's values. Some states have restricted the authority of family members who are not formally appointed proxies to terminate life-sustaining treatments from mentally incapacitated but conscious patients.",
"     </li>",
"     <li>",
"      Physician-patient and physician-family communication is essential for",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      satisfaction with care; an open dialogue is encouraged. Summaries of these interactions and a detailed description of the decision making process should be included in the medical record as they both relate to decisions about current care and can potentially help in future care decisions.",
"     </li>",
"     <li>",
"      Physicians should initiate discussions early in the course of a terminal illness in order to approach these sensitive issues in a gradual way and in order to assure that the patient's wishes are accurately represented.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/1\">",
"      Meisel A, Snyder L, Quill T, American College of Physicians--American Society of Internal Medicine End-of-Life Care Consensus Panel. Seven legal barriers to end-of-life care: myths, realities, and grains of truth. JAMA 2000; 284:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/2\">",
"      Studdert DM, Mello MM, Sage WM, et al. Defensive medicine among high-risk specialist physicians in a volatile malpractice environment. JAMA 2005; 293:2609.",
"     </a>",
"    </li>",
"    <li>",
"     Hippocrates. The art. In: Hippocrates: The Loeb classical library, Jones WHS (Ed), Harvard University Press, Cambridge 1923.",
"    </li>",
"    <li>",
"     Bigelow J. Self-limited disease: address to the Massachusetts Medical Society, May 27, 1835. In: Nature in disease, Ticknor and Fields, Boston 1854.",
"    </li>",
"    <li>",
"     Warren J. Etherization, with surgical remarks, Ticknor &amp; Co, Boston 1848.",
"    </li>",
"    <li>",
"     Pope Pius XII. The prolongation of life. In: Ethics in medicine, Reiser SJ, Dyck AJ, Curran WJ (Eds), MIT Press, Cambridge 1997.",
"    </li>",
"    <li>",
"     In re Quinlan, 70 N.J. 10 (1976).",
"    </li>",
"    <li>",
"     Cruzan v. Director of Missouri Department of Health, 110 S. Ct. 2841 (1990).",
"    </li>",
"    <li>",
"     In re Conroy, 98 N.J. 321 (1985).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/10\">",
"      Emanuel EJ. A review of the ethical and legal aspects of terminating medical care. Am J Med 1988; 84:291.",
"     </a>",
"    </li>",
"    <li>",
"     Pabon v. Wright, 459 F. 3d. 241 (2006).",
"    </li>",
"    <li>",
"     Washington v Glucksberg, 117 S. Ct. 2258 (1997).",
"    </li>",
"    <li>",
"     Vacco v Quill, 117 S. Ct. 2293 (1997).",
"    </li>",
"    <li>",
"     Gonzales v. Oregon, 126 S. Ct. 904 (2006).",
"    </li>",
"    <li>",
"     Medical Ethics, 2nd, Veatch RM (Ed), Jones and Bartlett, Boston 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/16\">",
"      Silveira MJ, Kim SY, Langa KM. Advance directives and outcomes of surrogate decision making before death. N Engl J Med 2010; 362:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/17\">",
"      Hickman SE, Sabatino CP, Moss AH, Nester JW. The POLST (Physician Orders for Life-Sustaining Treatment) paradigm to improve end-of-life care: potential state legal barriers to implementation. J Law Med Ethics 2008; 36:119.",
"     </a>",
"    </li>",
"    <li>",
"     Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 5th, Oxford, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/19\">",
"      Emanuel EJ, Emanuel LL. Proxy decision making for incompetent patients. An ethical and empirical analysis. JAMA 1992; 267:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/20\">",
"      Shalowitz DI, Garrett-Mayer E, Wendler D. The accuracy of surrogate decision makers: a systematic review. Arch Intern Med 2006; 166:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/21\">",
"      Hare J, Pratt C, Nelson C. Agreement between patients and their self-selected surrogates on difficult medical decisions. Arch Intern Med 1992; 152:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/22\">",
"      Seckler AB, Meier DE, Mulvihill M, Paris BE. Substituted judgment: how accurate are proxy predictions? Ann Intern Med 1991; 115:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/23\">",
"      White DB, Braddock CH 3rd, Bereknyei S, Curtis JR. Toward shared decision making at the end of life in intensive care units: opportunities for improvement. Arch Intern Med 2007; 167:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/24\">",
"      Wendler D, Rid A. Systematic review: the effect on surrogates of making treatment decisions for others. Ann Intern Med 2011; 154:336.",
"     </a>",
"    </li>",
"    <li>",
"     Wendland v. Wendland, 110 Cal. Rptr. 2d 412 (2001).",
"    </li>",
"    <li>",
"     In re Edna, MF 563 N.W.2d 485 (Wis. 1997).",
"    </li>",
"    <li>",
"     In re Martin, 538 N.W.2d 399 (Mich. 1995).",
"    </li>",
"    <li>",
"     Schiavo ex rel. Schindler v. Schiavo, 403 F.3d 1289 (2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/29\">",
"      Teno JM, Gruneir A, Schwartz Z, et al. Association between advance directives and quality of end-of-life care: a national study. J Am Geriatr Soc 2007; 55:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/30\">",
"      Miles SH. Informed demand for \"non-beneficial\" medical treatment. N Engl J Med 1991; 325:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/31\">",
"      Lynch HF, Mathes M, Sawicki NN. Compliance with advance directives. Wrongful living and tort law incentives. J Leg Med 2008; 29:133.",
"     </a>",
"    </li>",
"    <li>",
"     Bouvia v. Superior Court, 225 Cal. Rptr. 297 (1986).",
"    </li>",
"    <li>",
"     Kelly G. Medico-moral problems, The Catholic Hospital Association, St. Louis 1958.",
"    </li>",
"    <li>",
"     Brophy v. New England Sinai Hospital, 398 Mass. 417 (1986).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/35\">",
"      Meisel A. Legal myths about terminating life support. Arch Intern Med 1991; 151:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/36\">",
"      Schneiderman LJ, Jecker NS, Jonsen AR. Medical futility: its meaning and ethical implications. Ann Intern Med 1990; 112:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/37\">",
"      Truog RD, Brett AS, Frader J. The problem with futility. N Engl J Med 1992; 326:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/38\">",
"      Veatch RM. Why physicians cannot determine if care is futile. J Am Geriatr Soc 1994; 42:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/39\">",
"      Helft PR, Siegler M, Lantos J. The rise and fall of the futility movement. N Engl J Med 2000; 343:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/40\">",
"      Curtis JR, Park DR, Krone MR, Pearlman RA. Use of the medical futility rationale in do-not-attempt-resuscitation orders. JAMA 1995; 273:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/41\">",
"      Shanawani H, Wenrich MD, Tonelli MR, Curtis JR. Meeting physicians' responsibilities in providing end-of-life care. Chest 2008; 133:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/42\">",
"      Fine RL, Mayo TW. Resolution of futility by due process: early experience with the Texas Advance Directives Act. Ann Intern Med 2003; 138:743.",
"     </a>",
"    </li>",
"    <li>",
"     Ramshaw, E. &ldquo;Bills challenge care limits for terminally ill patients.&rdquo; Dallas Morning News, February 15, 2007.",
"    </li>",
"    <li>",
"     In re Mary Moe, 385 Mass. 555 (1982).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/45\">",
"      Torke AM, Alexander GC, Lantos J. Substituted judgment: the limitations of autonomy in surrogate decision making. J Gen Intern Med 2008; 23:1514.",
"     </a>",
"    </li>",
"    <li>",
"     In re Storar 52 N.Y. 2d 363 (1981).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/47\">",
"      Baumrucker SJ, Sheldon JE, Stolick M, et al. The ethical concept of \"best interest\". Am J Hosp Palliat Care 2008; 25:56.",
"     </a>",
"    </li>",
"    <li>",
"     The President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Deciding to Forego Life-sustaining treatment. U.S. Government Printing Office; Washington, DC 1983.",
"    </li>",
"    <li>",
"     file://www.usccb.org/bishops/directives.shtml#partfive .",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/50\">",
"      Gurm HS, Litaker DG. Framing procedural risks to patients: is 99% safe the same as a risk of 1 in 100? Acad Med 2000; 75:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/51\">",
"      Duffy FD. Dialogue: the core clinical skill. Ann Intern Med 1998; 128:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14473/abstract/52\">",
"      Levinson W, Roter DL, Mullooly JP, et al. Physician-patient communication. The relationship with malpractice claims among primary care physicians and surgeons. JAMA 1997; 277:553.",
"     </a>",
"    </li>",
"    <li>",
"     Jonsen AR, Siegler M, Winslade WJ. Clinical Ethics, 4th, McGraw-Holl, New York 1998.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2207 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14473=[""].join("\n");
var outline_f14_8_14473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WITHDRAWAL OF MEDICAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Historic perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The right to refuse medical interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192990306\">",
"      Physician-assisted suicide and its relationship to withholding treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Medical interventions that can be stopped",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessing decision-making capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surrogate decision makers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Family decisions in court",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Methods for making decisions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ordinary and extraordinary care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Futile treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Substituted judgment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Best interests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192990500\">",
"      Position of the US conference of Catholic bishops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192990527\">",
"      Addressing difficult cases in end-of-life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADVANCE DIRECTIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EUTHANASIA AND PHYSICIAN ASSISTED SUICIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMMUNICATION AND DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2207|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/18/27947\" title=\"table 1\">",
"      Living wills pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12938?source=related_link\">",
"      Communication in the ICU: Holding a family meeting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=related_link\">",
"      Ethics in the intensive care unit: Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24934?source=related_link\">",
"      Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=related_link\">",
"      Euthanasia and physician assisted suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_8_14474="Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection";
var content_f14_8_14474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14474/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14474/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14474/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/8/14474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/8/14474/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/8/14474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H32984734\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment in patients with chronic hepatitis C virus (HCV) infection is to eradicate hepatitis C virus (HCV) RNA, which is predicted by the attainment of a sustained virologic response (SVR). An SVR is associated with a 99 percent chance of being HCV RNA negative during long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/1\">",
"     1",
"    </a>",
"    ], and attaining an SVR has been associated with decreases in all-cause mortality, liver-related death, the need for liver transplantation, hepatocellular carcinoma rates, and liver-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H132344506\">",
"     'Definitions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will review factors associated with an SVR following treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for chronic HCV infection. Whether these factors also apply to patients with genotype 1 who are receiving therapy with peginterferon, ribavirin, and a protease inhibitor is unclear. The approach to the treatment of patients with chronic HCV, including patients who have failed to respond to or have relapsed following prior attempts at therapy, as well as the response to treatment with triple therapy (peginterferon, ribavirin, and a protease inhibitor) for patients with genotype 1 are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H132344506\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several terms that are used to describe the response to antiviral therapy in patients with chronic HCV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained virologic response (SVR): absence of HCV RNA by polymerase chain reaction six months after stopping treatment",
"     </li>",
"     <li>",
"      Early virologic response (EVR): at least a 2 log(10) reduction in HCV RNA (a partial EVR) or HCV RNA negativity (a complete EVR) by week 12 of treatment",
"     </li>",
"     <li>",
"      End of treatment response (EOT): HCV RNA negativity at the end of treatment",
"     </li>",
"     <li>",
"      Rapid virologic response (RVR): HCV RNA negativity after four weeks of treatment",
"     </li>",
"     <li>",
"      Delayed virologic response: HCV RNA positivity at week 12 but negative by week 24",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16092652\">",
"    <span class=\"h1\">",
"     VIRAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two of the most important predictors of a sustained virologic response (SVR) following combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    are the HCV genotype and, to a lesser extent, the baseline viral load (",
"    <a class=\"graphic graphic_figure graphicRef56726 graphicRef79643 graphicRef67449 \" href=\"UTD.htm?22/44/23235\">",
"     figure 1A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29780?source=see_link&amp;anchor=H5#H5\">",
"     \"Characteristics of the hepatitis C virus\", section on 'Genotypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher response rates are seen in patients with genotypes 2 or 3 than in those with genotype 1. Studies have estimated the following SVR rates based upon genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/8-18\">",
"     8-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genotype 1: 40 to 50 percent",
"     </li>",
"     <li>",
"      Genotype 2: 80 percent",
"     </li>",
"     <li>",
"      Genotype 3: 80 percent",
"     </li>",
"     <li>",
"      Genotype 4: 50 to 70 percent",
"     </li>",
"     <li>",
"      Genotype 5: 60 percent",
"     </li>",
"     <li>",
"      Genotype 6: 60 to 80 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher response rates are seen in those with lower baseline viral loads (&le;600,000 to 800,000",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/19\">",
"     19",
"    </a>",
"    ]. In one study that used a cut-off of 600,000",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    the odds ratio for attaining an SVR in those with a lower viral load was 3.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interferon sensitizing region within the HCV genome has been identified, but its role is less established [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16092940\">",
"    <span class=\"h1\">",
"     PATIENT-RELATED FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient-related factors that are associated with a sustained virologic response (SVR) include race, IL28B polymorphisms, and age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16094290\">",
"    <span class=\"h2\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Race is an important predictor of a response to treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . The highest response rates are seen in Asians [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/25\">",
"     25",
"    </a>",
"    ]. African Americans have lower response rates than whites, and Latino whites have lower response rates than non-Latino whites [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/20\">",
"     20",
"    </a>",
"    ]. These differences may be explained, at least in part, by variations in sites adjacent to the IL28B gene. (See",
"    <a class=\"local\" href=\"#H1571786\">",
"     'IL28B and race'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16094312\">",
"    <span class=\"h3\">",
"     African Americans",
"    </span>",
"    &nbsp;&mdash;&nbsp;African Americans generally have a lower response rate to interferon-based therapy compared with Caucasians. Representative studies demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 200 patients, African Americans had SVR rates of 19 percent, compared with 52 percent for whites (p&lt;0.001) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study with 401 patients also demonstrated lower response rates in African Americans compared with whites (28 versus 52 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was hypothesized that the lower response rate may be due to a higher prevalence of genotype 1 infection in African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/28\">",
"     28",
"    </a>",
"    ]. However, several studies have demonstrated that the SVR rate in African Americans is lower than in Caucasians, independent of genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/26,27,29-31\">",
"     26,27,29-31",
"    </a>",
"    ]. Lower response rates may be related to differences in the relative frequencies of IL28B polymorphisms and in the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    between African Americans and Caucasians. (See",
"    <a class=\"local\" href=\"#H1571786\">",
"     'IL28B and race'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32984741\">",
"     'Ribavirin dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16094319\">",
"    <span class=\"h3\">",
"     Latino whites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response rates in Latino whites appear to be lower than in non-Latino whites. The largest study to show such an association compared response rates in 269 Latino whites and 300 non-Latino whites treated with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/32\">",
"     32",
"    </a>",
"    ]. The SVR rate was significantly higher among non-Latino whites after adjusting for other characteristics (49 versus 34 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16092947\">",
"    <span class=\"h2\">",
"     IL28B polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IL28B gene encodes interferon lambda, which is involved in viral resistance and is upregulated by interferons. IL28B polymorphisms are strong independent predictors of viral responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/20,33-40\">",
"     20,33-40",
"    </a>",
"    ]. Multiple studies have shown that patients with the CC genotype at the rs12979860 polymorphic site have higher sustained virologic response (SVR) rates than patients with the CT or TT genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/20,33,36,38,39,41,42\">",
"     20,33,36,38,39,41,42",
"    </a>",
"    ]. Similarly, patients with the TT genotype at the rs8099917 polymorphic site have higher SVR rates than patients with the GT or GG genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/43-47\">",
"     43-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 17 studies with 4252 patients, among patients with HCV genotypes 1 or 4 (but not genotypes 2 or 3), the favorable rs12979860 genotype (CC) was associated with a higher chance of achieving an SVR than other genotypes (odds ratio [OR] 5.5, 95% confidence interval [CI] 3.7-8.2 for genotype 1 and OR 8.1, 95% CI 4.1-15.9 for genotype 4) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/48\">",
"     48",
"    </a>",
"    ]. Similarly, among patients with HCV genotype 1, the favorable rs8099917 genotype (TT) was associated with higher chance of achieving an SVR (OR 4.3, 95% CI 2.9-6.4).",
"   </p>",
"   <p>",
"    In a second meta-analysis with 21 studies and 6437 patients with HCV genotype 1, having a favorable IL28B genotype (either at the rs12979860 or rs8099917 sites) was also associated with an increased SVR rate (OR 4.7, 95% CI 3.8-5.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the importance of IL28B polymorphisms in patients with HCV genotype 1 who are being treated with a protease inhibitor in addition to peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is not yet clear. Data are limited in such patients, but there may be a higher response rate in some patients with favorable genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1571786\">",
"    <span class=\"h3\">",
"     IL28B and race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific IL28B polymorphisms are differentially represented in various racial groups, potentially accounting for some of the observed variations in response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/36,51\">",
"     36,51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16094290\">",
"     'Race'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a study of 1628 patients with HCV genotype 1 who underwent IL28B genotyping at the rs12979860 site, 1171 were Caucasian, 300 were African American, 116 were Hispanic, and 41 were of other races [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/20\">",
"     20",
"    </a>",
"    ]. One-half of patients had the CT genotype, regardless of race. The CC genotype was seen most commonly in Caucasians, whereas the TT genotype was seen most commonly in African Americans:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CC genotype: 37 percent of Caucasians, 14 percent of African Americans, 29 percent of Hispanics",
"     </li>",
"     <li>",
"      CT genotype: 51 percent of Caucasians, 49 percent of African Americans, 48 percent of Hispanics",
"     </li>",
"     <li>",
"      TT genotype: 12 percent of Caucasians, 37 percent of African Americans, 22 percent of Hispanics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caucasians had the highest SVR rates (46 percent), followed by Hispanics (41 percent) and African Americans (19 percent). In all groups, the presence of the CC genotype was associated with more than a twofold increase in SVR compared with the TT genotype. However, among patients with CC genotypes, Caucasians still had significantly higher SVR rates compared with Hispanics and African Americans (69 versus 56 and 48 percent, respectively). On multivariable analysis, IL28B genotype CC was the strongest predictor of an SVR. Race, even after controlling for IL28B genotype, baseline viral load, stage of hepatic fibrosis, and fasting glucose level, remained a significant predictor of an SVR. The odds ratios for attaining an SVR on multivariable analysis were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CC genotype verus non-CC: 5.2",
"     </li>",
"     <li>",
"      Caucasian versus African American race: 2.8",
"     </li>",
"     <li>",
"      Hispanic versus African American race: 2.1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CC genotype appears to be particularly prevalent in Asians. In a study of the Chinese Han population, 88 percent had the CC genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/52\">",
"     52",
"    </a>",
"    ]. Similarly, 88 percent of patients from Korea had the CC genotype in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 404 Egyptians, the CC genotype was noted in 48 percent of healthy patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the rs8099917 polymorphism, the association was stronger among Asian patients than among Caucasian patients (OR 8.1 versus 3.0). In addition, among Asian patients, the favorable rs8099917 genotype was also associated with an SVR in patients with HCV genotypes 2 and 3 (OR 1.99, 95% CI 1.1-3.6).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1571808\">",
"    <span class=\"h3\">",
"     Other associations with IL28B",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL28B polymorphisms have also been associated with pretreatment low-density lipoprotein (LDL) levels and hepatic steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients with the CC genotype had higher pretreatment LDL levels and less steatosis. These associations could in part explain the higher SVR rates noted in patients with less steatosis and higher pretreatment LDL levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14409014\">",
"    <span class=\"h2\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCV who demonstrate insulin resistance tend to have a lower SVR rate. In a meta-analysis of 17 studies, normal insulin sensitivity was associated with a higher rate of SVR compared with insulin resistance (odds ratio 2.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of insulin resistance with lower treatment response rates provided the rationale for a controlled trial of an insulin sensitizing agent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/57\">",
"     57",
"    </a>",
"    ]. A total of 123 patients with chronic HCV genotype 1 and insulin resistance were randomly assigned to peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    . There were no significant differences in SVR rates overall, although in a subgroup analysis, the SVR rate was higher among women who received metformin (58 versus 29 percent). More studies are needed before this approach can be recommended.",
"   </p>",
"   <p>",
"    Similarly, a trial of 150 patients with HCV genotype 1 and insulin resistance assigned patients to either treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , or peginterferon, ribavirin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/58\">",
"     58",
"    </a>",
"    ]. There was no difference between the groups with regard to mean decrease in viral load after 12 weeks of treatment (the study's primary endpoint).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14409021\">",
"    <span class=\"h2\">",
"     Patients with elevated body weight and high viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with genotype 1, a high viral load at baseline (&ge;400,000",
"    <span class=\"nowrap\">",
"     IU/mL),",
"    </span>",
"    and body weight &ge;85 kg have poor responses to treatment with standard peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether higher doses of peginterferon",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    lead to higher SVR rates was studied in a trial with 1175 patient. Patients were assigned to one of four groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group A (standard of care): Peginterferon alfa-2a 180",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 48 weeks",
"     </li>",
"     <li>",
"      Group B: Peginterferon alfa-2a 180",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      1400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (weight &lt;95 kg) or 1600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (weight &ge;95 kg) for 48 weeks",
"     </li>",
"     <li>",
"      Group C: Peginterferon alfa-2a 360",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      for 12 weeks and then 180",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      for 36 weeks, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for all 48 weeks",
"     </li>",
"     <li>",
"      Peginterferon alfa-2a 360",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      for 12 weeks and then 180",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      for 36 weeks, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      1400 or 1600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for all 48 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with patients receiving standard of care, there was no increase in SVR rates for those receiving the higher doses of peginterferon",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (SVR rates of 38, 43, 44, and 41 percent, respectively, for groups A, B, C, and D).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31304968\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone successful treatment for hepatocellular carcinoma (HCC) may have a lower response rate to treatment compared with other patients with HCV. In a case control study, 82 patients with HCV who had undergone successful treatment for HCC were compared with 87 control patients who had cirrhosis due to HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/60\">",
"     60",
"    </a>",
"    ]. The patients were all treated with peginterferon and weight-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Patients in the HCC group had significantly lower response rates to treatment compared with the cirrhosis group (49 versus 64 percent). Subgroup analyses found a lower SVR rate for HCC patients with genotype 1 (33 versus 61 percent), but not for HCC patients with genotype 2 or 3 (71 percent for both groups). In addition, among patients who were 80 percent adherent to therapy, there was no significant difference in SVR rate between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160773597\">",
"    <span class=\"h2\">",
"     Portal hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of portal hypertension may lower response rates to antiviral therapy. In a study of 90 patients (82 percent with HCV genotype 1 or 4), a hepatic venous pressure gradient of 10 mmHg or higher was an independent risk factor for treatment failure with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (odds ratio 14.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16092975\">",
"    <span class=\"h2\">",
"     Other predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that have been associated with higher sustained virologic response (SVR) rates include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/57,62-73\">",
"     57,62-73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Absence of bridging fibrosis or cirrhosis",
"     </li>",
"     <li>",
"      Absence of significant (&gt;33 percent) hepatic steatosis",
"     </li>",
"     <li>",
"      Lower pretreatment triglyceride levels",
"     </li>",
"     <li>",
"      Higher pretreatment low-density lipoprotein levels",
"     </li>",
"     <li>",
"      Lower pretreatment high-density lipoprotein levels",
"     </li>",
"     <li>",
"      Statin use",
"     </li>",
"     <li>",
"      Serum vitamin A and D levels",
"     </li>",
"     <li>",
"      High levels of coffee consumption",
"     </li>",
"     <li>",
"      Carrier of the HLA DQB1*0301 allele",
"     </li>",
"     <li>",
"      Vitamin B12 supplementation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, early menopause has been associated with lower SVR rates in women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16093397\">",
"    <span class=\"h1\">",
"     TREATMENT-RELATED FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-related factors that are associated with a sustained virologic response (SVR) include the use of weight-based dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , maintaining full dose therapy, and treatment adherence. In addition, changes in the viral load during treatment are associated with an SVR. Finally, in patients with genotype 1, the addition of a protease inhibitor is associated with increased SVR rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404547\">",
"    <span class=\"h2\">",
"     Choice of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peginterferon is superior to standard interferon for treating chronic HCV infection. Two forms of peginterferon are available: peginterferon alfa-2a and peginterferon alfa-2b. Data suggest that the sustained virologic response rates are higher in patients treated with peginterferon alfa-2a. In addition, combination therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is superior to peginterferon monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32984741\">",
"    <span class=\"h2\">",
"     Ribavirin dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study suggested that response rates may be improved with weight-based dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/11\">",
"     11",
"    </a>",
"    ]. This hypothesis was tested directly in a controlled trial that included 5027 patients who were randomly assigned to peginterferon alfa-2b plus ribavirin, given either as a fixed dose (800 mg daily) or by weight (800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for those &lt;65 kg, 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for those 65 to &lt;85 kg, 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for those 85 to &lt;105 kg, and 1400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for those 105 to 125 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sustained virologic response rates were higher with the weight-based dosing regimen in an intention-to-treat analysis (44 versus 41 percent). Statistically significant benefits of weight-based dosing were observed in patients with genotype 1 (34 versus 29 percent) but not in patients with genotype 2 or 3 (62 versus 60 percent). Serious adverse events were similar in both arms.",
"   </p>",
"   <p>",
"    However, weight-based dosing may not result in adequate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    concentrations in all patients. In a study of 145 patients with HCV genotype 1 who received &gt;90 percent of the prescribed peginterferon and weight-based ribavirin, patients with ribavirin exposure of &ge;4480",
"    <span class=\"nowrap\">",
"     ng/mL/day",
"    </span>",
"    in the first week had higher SVR rates than those with lower levels of exposure (57 versus 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/76\">",
"     76",
"    </a>",
"    ]. Among those with ribavirin exposure of &ge;4480",
"    <span class=\"nowrap\">",
"     ng/mL/day,",
"    </span>",
"    similar SVR rates were seen in Caucasians and African Americans (60 and 52 percent, respectively). However, Caucasians were more likely than African Americans to have a ribavirin exposure of &ge;4480",
"    <span class=\"nowrap\">",
"     ng/mL/day",
"    </span>",
"    during the first week (64 versus 44 percent) and had higher SVR rates overall (55 versus 37 percent). This study suggests that variability in ribavirin exposure may explain some of the differences in SVR rates seen between Caucasians and African Americans. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32984748\">",
"    <span class=\"h2\">",
"     Dose reduction and adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adherence to the prescribed doses of therapy is an important determinant of a sustained virologic response (SVR), particularly in patients infected with HCV genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/77\">",
"     77",
"    </a>",
"    ]. However, data on the impact of dose reduction for either peginterferon or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    are somewhat contradictory.",
"   </p>",
"   <p>",
"    The following conclusions were reached in the largest studies to evaluate the impact of dose reductions or discontinuation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report included 936 patients with advanced fibrosis or cirrhosis who had failed prior antiviral treatment and were undergoing retreatment with peginterferon alfa and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      during the lead-in phase of the HALT-C trial [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/78\">",
"       78",
"      </a>",
"      ]. Patients who received &le;60 percent of the full dose of peginterferon had a reduced SVR compared with patients who received at least 98 percent of the prescribed dose (5 versus 17 percent). A reduction in the dose of ribavirin from the full dose (&ge;98 percent) to &le;60 percent did not affect the SVR if the ribavirin dose was not interrupted for more than seven consecutive days. However, if ribavirin was prematurely discontinued, the SVR rate dropped to &le;4 percent.",
"     </li>",
"     <li>",
"      A retrospective analysis of two large phase III clinical trials demonstrated that when the dose of interferon (or peginterferon)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      was reduced below 80 percent of that originally prescribed, or if the medications were discontinued before the patient received 80 percent of the planned duration of therapy, there was a significant decline in SVR [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/79\">",
"       79",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Of the 511 patients included in the analysis, those who received more than 80 percent of their interferon and ribavirin for more than 36 weeks (80 percent of the planned 48 weeks of therapy) had an SVR rate of 63 percent. By contrast, those who received less than 80 percent of the interferon",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ribavirin or discontinued treatment prior to completing 80 percent of the planned 48 weeks of therapy had an SVR rate of only 52 percent. This difference was almost entirely confined to patients infected with genotype 1 in whom the SVR declined from a maximum of 63 percent in patients who were able to remain on full-dose interferon and ribavirin for the entire duration of therapy to 34 percent in those whose dose was reduced or whose treatment was discontinued early.",
"      <br/>",
"      <br/>",
"      The timing of the dose reduction is also an important determinant of an SVR. Patients who were fully compliant with therapy during the entire 48 weeks of therapy had an SVR of 62 percent (178 of 287). Patients who reduced the dose of interferon or ribavirin to less than 80 percent after week 12 or stopped treatment after receiving 80 percent of the planned duration of therapy had an SVR rate of 51 percent (61 of 119). By contrast, patients who either had their dose reduced or discontinued treatment before week 12 had an SVR rate of 34 percent.",
"     </li>",
"     <li>",
"      A controlled trial of 516 patients evaluated patients with genotype 1 infection who had achieved a virologic response at week 24. Patients were randomly assigned to continue combination therapy or to peginterferon alone [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/80\">",
"       80",
"      </a>",
"      ]. The SVR rate was significantly higher in those who continued combination therapy (68 versus 53 percent), suggesting that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      helps maintain the virologic response. On the other hand, patients who achieve a rapid virologic response have a high SVR rate even if they prematurely discontinue ribavirin [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/81\">",
"       81",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H32984783\">",
"       'Rapid virologic response'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation of the studies looking at the impact of dose reductions on SVR is that they were performed retrospectively using data from phase III clinical trials that were not designed to evaluate the impact of adherence on SVR. In addition, most \"non-adherence\" was secondary to clinician and protocol mandated dose reductions in response to adverse events. While this information may be useful in the management of patients receiving peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for treatment of chronic HCV, the limitations of such analyses must be kept in mind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32984755\">",
"    <span class=\"h2\">",
"     Treatment-related side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop anemia during treatment may have higher sustained virologic response (SVR) rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. A study of 3023 treatment-na&iuml;ve genotype 1 patients being treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    found that patients whose hemoglobin dropped by more than 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    were more likely to attain an SVR than patients whose hemoglobin dropped by 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or less (44 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, patients with early onset anemia (eight weeks or fewer after starting treatment) who received erythropoiesis-stimulating agents had higher SVR rates than those who did not receive such agents (45 versus 26 percent). However, the use of erythropoiesis-stimulating agents in patients who developed anemia more than eight weeks after starting treatment did not have an effect on SVR rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Use of erythropoietic growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher response rates also appear to correlate with the degree of reduction in body weight and a decline in platelet and white blood cell counts during treatment, suggesting a connection with intrinsic interferon sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32984769\">",
"    <span class=\"h2\">",
"     Changes in viral load during treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once therapy has been started, the likelihood that a patient will fail to achieve a sustained virologic response (SVR) can be predicted by the virologic response at 12 weeks of therapy, and probably even earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/9,11,12,85-88\">",
"     9,11,12,85-88",
"    </a>",
"    ]. The rapidity of the virologic response also appears to be an important predictor of an SVR.",
"   </p>",
"   <p>",
"    These observations form the basis for current clinical recommendations regarding the termination of treatment in patients who are unlikely to respond. They have also stimulated a growing number of studies evaluating approaches that tailor therapy based upon the change in viral load during therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32984776\">",
"    <span class=\"h3\">",
"     Early virologic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early virologic response (EVR) is defined as at least a 2 log(10) reduction in HCV RNA (a partial EVR) or HCV RNA negativity (a complete EVR) by week 12. An SVR is unlikely in patients who fail to attain an EVR (less than 2 percent), with a negative predictive value that approaches 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/9,11,85,86\">",
"     9,11,85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who have an EVR, an SVR is attained in approximately 65 percent overall and in up to 72 percent in those with a complete EVR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/11,85\">",
"     11,85",
"    </a>",
"    ]. The likelihood of achieving an EVR is significantly lower in those with genotype 1, those with a baseline HCV RNA level greater than 800,000",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    and those who have poor adherence to therapy within the first 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/9,11,85,86\">",
"     9,11,85,86",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16092652\">",
"     'Viral factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H32984748\">",
"     'Dose reduction and adherence'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32984783\">",
"    <span class=\"h3\">",
"     Rapid virologic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;How quickly the HCV RNA declines following the initiation of treatment is an important predictor of an SVR, especially in patients with genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/86,89\">",
"     86,89",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16092652\">",
"     'Viral factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A rapid virologic response (RVR, defined as HCV RNA negative at four weeks) is a strong predictor of an SVR and may be an important factor when deciding how long treatment should be continued. Increased RVR rates have been associated with favorable IL28B polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16092947\">",
"     'IL28B polymorphisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 1121 patients were assigned to treatment with peginterferon alfa-2a plus placebo, peginterferon alfa-2a plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , or standard",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      plus ribavirin [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/86\">",
"       86",
"      </a>",
"      ]. Patients underwent HCV RNA testing at 4, 12, and 24 weeks. Patients with HCV genotype 1 with an RVR had an SVR rate of over 90 percent, regardless of which treatment they received. By contrast, patients who were still HCV RNA positive at week 4 but went on to become HCV RNA negative at weeks 12 or 24 had SVR rates of 60 to 72 percent and 43 to 48 percent, respectively. These data suggest that patients who become HCV RNA negative rapidly (by four weeks) represent a group of patients who are highly responsive to the effects of interferon.",
"     </li>",
"     <li>",
"      In a second study of 516 patients with genotype 1 or 4, 150 patients (29 percent) achieved an RVR with peginterferon alfa-2a plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . The patients who achieved an RVR received treatment for a total of 24 weeks instead of 48 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/90\">",
"       90",
"      </a>",
"      ]. The SVR rates were 79 and 87 percent in patients infected with genotypes 1 and 4, respectively. No baseline factors predicted an SVR in the subgroup of patients who achieved an RVR.",
"     </li>",
"     <li>",
"      A meta-analysis of seven studies with 807 patients examined whether 24 weeks of treatment (as opposed to 48 weeks) was sufficient in patients with HCV genotype 1 who achieved an RVR [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/91\">",
"       91",
"      </a>",
"      ]. Patients treated for only 24 weeks had a 14 percent lower SVR rate than those treated for 48 weeks due primarily to a higher relapse rate. However, shorter therapy did appear effective in patients with low baseline HCV RNA levels (400,000",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      or less). In that subgroup, there was no significant difference in SVR rates between 24 and 48 weeks of treatment.",
"     </li>",
"     <li>",
"      A retrospective analysis of 159 patients found that patients who failed to attain at least a 1 log decrease in viral load at four weeks had a low SVR rate [",
"      <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/92\">",
"       92",
"      </a>",
"      ]. Thirty-eight patients (24 percent) did not achieve a 1 log decrease in viral load at four weeks, of whom only three (8 percent) achieved an SVR. On the other hand, of the 46 patients (29 percent) who achieved an RVR, the SVR rate was 80 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19313132\">",
"    <span class=\"h3\">",
"     Influence of the specific assay for HCV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several commercial methods available to measure HCV RNA. A report from the HALT-C trial suggested that the Bayer Versant HCV RNA Qualitative (TMA) assay may be a better predictor of SVR than PCR-based assays [",
"    <a class=\"abstract\" href=\"UTD.htm?14/8/14474/abstract/93\">",
"     93",
"    </a>",
"    ]. The TMA can detect levels of HCV viremia of 5 to 10",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    or less, whereas PCR has a lower limit of detection of approximately 50 to 100",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TMA negativity at weeks 12 and 20 was significantly more predictive of an SVR than PCR negativity (82 versus 64 percent at week 12 and 66 versus 52 percent at week 20). An SVR was more likely the earlier the TMA became negative during treatment. Among 45 patients who were TMA-positive but PCR-negative at weeks 20 and 24, none achieved an SVR. Approximately 10 percent of patients with a single positive TMA at the end of treatment achieved an SVR; a single positive TMA test did not exclude SVR, although a persistently positive test did.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16093500\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment in patients with chronic hepatitis C virus (HCV) infection is to eradicate hepatitis C virus (HCV) RNA, which is predicted by the attainment of a sustained virologic response (SVR). An SVR is associated with a 99 percent chance of being HCV RNA negative during long-term follow-up. (See",
"    <a class=\"local\" href=\"#H32984734\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral-, patient-, and treatment-related factors are associated with achieving an SVR following treatment with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for chronic HCV infection.",
"     </li>",
"     <li>",
"      Two of the most important predictors of an SVR following combination therapy with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      are the HCV genotype and, to a lesser extent, the baseline viral load. (See",
"      <a class=\"local\" href=\"#H16092652\">",
"       'Viral factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Race is an important predictor of a response to treatment with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . African Americans have lower response rates than whites, and Latino whites have lower response rates than non-Latino whites. (See",
"      <a class=\"local\" href=\"#H16094290\">",
"       'Race'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymorphisms in sites adjacent to the IL28B gene are strongly associated with the response to therapy with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . Multiple studies have shown that patients with the CC genotype have higher SVR rates than patients with the CT or TT genotypes. (See",
"      <a class=\"local\" href=\"#H16092947\">",
"       'IL28B polymorphisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors that have been associated with higher rates of an SVR include age, body mass index, and insulin resistance. (See",
"      <a class=\"local\" href=\"#H16092975\">",
"       'Other predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment-related factors that are associated with an SVR include the use of weight-based dosing of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , maintaining full dose therapy, and treatment adherence. (See",
"      <a class=\"local\" href=\"#H16093397\">",
"       'Treatment-related factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once therapy has been started, the likelihood that a patient will fail to achieve an SVR can be predicted based upon the virologic response at 12 weeks of therapy. Patients without an early virologic response (EVR) have less than a 2 percent chance of achieving an SVR, compared with an SVR rate of 65 percent in patients with an EVR. The rapidity of the virologic response also appears to be an important predictor of an SVR. (See",
"      <a class=\"local\" href=\"#H32984769\">",
"       'Changes in viral load during treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who achieve a rapid virologic response (undetectable HCV RNA by PCR at week 4) and maintain it at weeks 12 and 24 have more than a 90 percent chance of achieving an SVR. (See",
"      <a class=\"local\" href=\"#H32984783\">",
"       'Rapid virologic response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/1\">",
"      Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/2\">",
"      Backus L, Boothroyd DB, Phillips BR, et al. Impact of sustained virologc response to  pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: The US Department of Veterans Affairs' experience. Hepatology 2010; 52:428A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/3\">",
"      Russo MW. Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. Expert Rev Gastroenterol Hepatol 2010; 4:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/4\">",
"      Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/5\">",
"      Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/6\">",
"      Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/7\">",
"      Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/8\">",
"      Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/9\">",
"      Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/10\">",
"      Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/11\">",
"      Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/12\">",
"      Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/13\">",
"      El-Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 na&iuml;ve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005; 100:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/14\">",
"      Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/15\">",
"      Legrand-Abravanel F, Sandres-Saun&eacute; K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004; 189:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/16\">",
"      Hui CK, Yuen MF, Sablon E, et al. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/17\">",
"      Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/18\">",
"      Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010; 52:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/19\">",
"      Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/20\">",
"      Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/21\">",
"      Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/22\">",
"      El-Shamy A, Shoji I, El-Akel W, et al. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 2012; 50:3886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/23\">",
"      El-Shamy A, Shoji I, Kim SR, et al. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One 2012; 7:e30513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/24\">",
"      El-Shamy A, Nagano-Fujii M, Sasase N, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/25\">",
"      Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008; 14:3416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/26\">",
"      Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/27\">",
"      Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/28\">",
"      Shiffman ML, Mills P, Moonka DK, et al. Enhanced efficacy of pegylated (40 kd) interferon alfa-2A (Pegasys) compared with interferon alfa-2A (Roferon-A) for chronic hepatitis C in blacks (abstract). Hepatology 2000; 32:348A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/29\">",
"      Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/30\">",
"      Shiffman ML, Mihas AA, Millwala F, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007; 102:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/31\">",
"      Jacobson IM, Brown RS Jr, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/32\">",
"      Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/33\">",
"      McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/34\">",
"      Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/35\">",
"      Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/36\">",
"      Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/37\">",
"      Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/38\">",
"      Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/39\">",
"      Montes-Cano MA, Garc&iacute;a-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/40\">",
"      Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/41\">",
"      De Nicola S, Aghemo A, Rumi MG, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/42\">",
"      Asselah T, De Muynck S, Bro&euml;t P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/43\">",
"      St&auml;ttermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-na&iuml;ve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/44\">",
"      Sakamoto N, Nakagawa M, Tanaka Y, et al. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 2011; 83:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/45\">",
"      Doehring A, Hofmann WP, Schlecker C, et al. Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir Ther 2010; 15:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/46\">",
"      Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-&alpha; and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010; 5:e13771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/47\">",
"      Huang CF, Huang JF, Yang JF, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012; 56:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/48\">",
"      Chen Y, Xu HX, Wang LJ, et al. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-&alpha; and ribavirin. Aliment Pharmacol Ther 2012; 36:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/49\">",
"      Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012; 36:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/50\">",
"      Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/51\">",
"      Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/52\">",
"      Liao XW, Ling Y, Li XH, et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 2011; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/53\">",
"      Lyoo K, Song MJ, Hur W, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 2011; 52:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/54\">",
"      El-Awady MK, Mostafa L, Tabll AA, et al. Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon 2012; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/55\">",
"      Clark PJ, Thompson AJ, Zhu M, et, al. IL28B genetic polypmorphism has genome wide significant associations with serum low denisty lipoprotein levels and hepatic steatosis in patients with genotype 1 chronic hepatitis C (CHC). Hepatology 2010; 52:439A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/56\">",
"      Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/57\">",
"      Romero-G&oacute;mez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in na&iuml;ve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/58\">",
"      Harrison SA, Hamzeh FM, Han J, et al. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012; 56:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/59\">",
"      Reddy KR, Shiffman ML, Rodriguez-Torres M, et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 2010; 139:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/60\">",
"      Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. J Hepatol 2011; 54:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/61\">",
"      Reiberger T, Rutter K, Ferlitsch A, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2011; 9:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/62\">",
"      Romero-G&oacute;mez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/63\">",
"      Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/64\">",
"      Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/65\">",
"      Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/66\">",
"      Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/67\">",
"      Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011; 140:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/68\">",
"      Bitetto D, Fattovich G, Fabris C, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/69\">",
"      Freedman ND, Curto TM, Lindsay KL, et al. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011; 140:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/70\">",
"      de Rueda PM, L&oacute;pez-Nevot M&Aacute;, S&aacute;enz-L&oacute;pez P, et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 2011; 106:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/71\">",
"      Hu CC, Lin CL, Kuo YL, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/72\">",
"      Bitetto D, Bortolotti N, Falleti E, et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology 2013; 57:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/73\">",
"      Rocco A, Compare D, Coccoli P, et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut 2013; 62:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/74\">",
"      Villa E, Karampatou A, Camm&agrave; C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/75\">",
"      Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/76\">",
"      Jin R, Cai L, Tan M, et al. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. Am J Gastroenterol 2012; 107:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/77\">",
"      Lo Re V 3rd, Teal V, Localio AR, et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011; 155:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/78\">",
"      Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/79\">",
"      McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/80\">",
"      Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/81\">",
"      Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/82\">",
"      Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/83\">",
"      Sievert W, Dore GJ, McCaughan GW, et al. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011; 53:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/84\">",
"      Lindsay KL, Morishima C, Wright EC, et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/85\">",
"      Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/86\">",
"      Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/87\">",
"      Wong JB, Davis GL, McHutchison JG, et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/88\">",
"      Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/89\">",
"      Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/90\">",
"      Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/91\">",
"      Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/92\">",
"      Reau N, Satoskar R, Te H, et al. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol 2011; 106:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/8/14474/abstract/93\">",
"      Morishima C, Morgan TR, Everhart JE, et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006; 44:360.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15783 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14474=[""].join("\n");
var outline_f14_8_14474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16093500\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32984734\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H132344506\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16092652\">",
"      VIRAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16092940\">",
"      PATIENT-RELATED FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16094290\">",
"      Race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16094312\">",
"      - African Americans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16094319\">",
"      - Latino whites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16092947\">",
"      IL28B polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1571786\">",
"      - IL28B and race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1571808\">",
"      - Other associations with IL28B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14409014\">",
"      Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14409021\">",
"      Patients with elevated body weight and high viral load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31304968\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160773597\">",
"      Portal hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16092975\">",
"      Other predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16093397\">",
"      TREATMENT-RELATED FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6404547\">",
"      Choice of medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32984741\">",
"      Ribavirin dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32984748\">",
"      Dose reduction and adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32984755\">",
"      Treatment-related side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32984769\">",
"      Changes in viral load during treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32984776\">",
"      - Early virologic response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32984783\">",
"      - Rapid virologic response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19313132\">",
"      - Influence of the specific assay for HCV RNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16093500\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/15783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15783|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/42/18094\" title=\"figure 1A\">",
"      SVR genotype AASLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/37/42590\" title=\"figure 1B\">",
"      SVR dose genotype AASLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/42/34478\" title=\"figure 1C\">",
"      SVR genotype viral load AASLD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29780?source=related_link\">",
"      Characteristics of the hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=related_link\">",
"      Response-guided therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_8_14475="Causes alveolar proteinosis";
var content_f14_8_14475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary alveolar proteinosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Congenital",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutations in surfactant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutations in GM-CSF receptor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Secondary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allogeneic bone marrow transplantation for myeloid malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hematologic malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infections (eg, Nocardia, Pneumocystis jirovecii, viral)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pneumoconioses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Acute silica inhalation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Aluminum dust inhalation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Titanium inhalation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acquired",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anti-GM-CSF antibodies",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GM-CSF: granulocyte macrophage-colony stimulating factor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14475=[""].join("\n");
var outline_f14_8_14475=null;
var title_f14_8_14476="Cervical length twins and PTB";
var content_f14_8_14476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prediction of preterm birth before 32 weeks of gestation in twins by sonographically determined cervical length",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Cut-off for cervical length (mm)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sensitivity (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Specificity (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       PPV (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       NPV (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Assessment at 21 to 24 weeks of gestation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       20",
"      </td>",
"      <td>",
"       42",
"      </td>",
"      <td>",
"       85",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       94",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       25",
"      </td>",
"      <td>",
"       54",
"      </td>",
"      <td>",
"       86",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       95",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       30",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       89",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       97",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Assessment at 25 to 28 weeks of gestation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       20",
"      </td>",
"      <td>",
"       56",
"      </td>",
"      <td>",
"       76",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       95",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       25",
"      </td>",
"      <td>",
"       63 to 100",
"      </td>",
"      <td>",
"       70 to 84",
"      </td>",
"      <td>",
"       13 to 18",
"      </td>",
"      <td>",
"       96 to 100",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; NPV: negative predictive value.",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from:",
"     <br>",
"      1. Goldenberg, RL, Iams, JD, Miodovnik, M, et al. The preterm prediction study: risk factors in twin gestations. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1996; 175:1047.",
"      <br>",
"       2. Guzman, ER, Walters, C, O'Reilly-Green, C, et al. Use of cervical ultrasonography in prediction of spontaneous preterm birth in twin gestations. Am J Obstet Gynecol 2000; 183:1103.",
"       <br>",
"        3. Vayssiere, C, Favre, R, Audibert, F, et al. Cervical length and funneling at 22 and 27 weeks to predict spontaneous birth before 32 weeks in twin pregnancies: a French prospective multicenter study. Am J Obstet Gynecol 2002; 187:1596.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14476=[""].join("\n");
var outline_f14_8_14476=null;
var title_f14_8_14477="Antimicrobial";
var content_f14_8_14477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial agents for the management of superficial partial thickness burns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristics/antimicrobial agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effectiveness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silver sulfasalazine (SSD)",
"       </td>",
"       <td>",
"        Small, medium and large surface area burns",
"       </td>",
"       <td>",
"        <p>",
"         No evidence to support improved would healing or reduction in bacterial wound infections",
"        </p>",
"        <p>",
"         Decreased colonization of wounds",
"        </p>",
"        <p>",
"         Alleviates pain",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Burns near eyes",
"        </p>",
"        <p>",
"         Pregnant",
"        </p>",
"        <p>",
"         Breast feeding",
"        </p>",
"        <p>",
"         Newborns &lt;2 months",
"        </p>",
"        <p>",
"         Allergic to sulfonamides",
"        </p>",
"        <p>",
"         Signs of re-epithelialization",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Skin hypersensitivity",
"        </p>",
"        <p>",
"         Neutropenia",
"        </p>",
"        <p>",
"         Leukopenia",
"        </p>",
"        <p>",
"         Methemoglobinemia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        SSD plus cerium",
"       </td>",
"       <td>",
"        Small, medium and large surface area burns",
"       </td>",
"       <td>",
"        Improved re-epithelialization over SSD alone",
"       </td>",
"       <td>",
"        <p>",
"         Burns near eyes",
"        </p>",
"        <p>",
"         Pregnancy",
"        </p>",
"        <p>",
"         Breast feeding",
"        </p>",
"        <p>",
"         Newborns &lt;2 months",
"        </p>",
"        <p>",
"         Allergic to sulfonamides",
"        </p>",
"        <p>",
"         Signs of re-epithelialization",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Skin hypersensitivity",
"        </p>",
"        <p>",
"         Neutropenia",
"        </p>",
"        <p>",
"         Leukopenia",
"        </p>",
"        <p>",
"         Methemoglobinemia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Combination antibiotic ointments",
"       </td>",
"       <td>",
"        <p>",
"         Face",
"        </p>",
"        <p>",
"         Ears",
"        </p>",
"        <p>",
"         Perineum",
"        </p>",
"        <p>",
"         Allergies to sulfonamides",
"        </p>",
"       </td>",
"       <td>",
"        Ease of application and of removal",
"       </td>",
"       <td>",
"        <p>",
"         Bacterial resistance",
"        </p>",
"        <p>",
"         Allergic reaction",
"        </p>",
"        <p>",
"         Signs of re-epithelialization",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Yeast colonization",
"        </p>",
"        <p>",
"         Skin hypersensitivity",
"        </p>",
"        <p>",
"         Ototoxicity and nephrotoxicity with Neosporin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mafenide",
"       </td>",
"       <td>",
"        <p>",
"         Ears",
"        </p>",
"        <p>",
"         Nose",
"        </p>",
"        <p>",
"         Dense bacterial proliferation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Excellent eschar penetration",
"        </p>",
"        <p>",
"         Penetrates cartilage",
"        </p>",
"       </td>",
"       <td>",
"        Burns &gt;40 percent total body surface area",
"       </td>",
"       <td>",
"        <p>",
"         Metabolic acidosis",
"        </p>",
"        <p>",
"         Painful",
"        </p>",
"        <p>",
"         Inhibits epithelial regeneration",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Chlorhexidine",
"       </td>",
"       <td>",
"        Only superficial burns",
"       </td>",
"       <td>",
"        <p>",
"         Does not interfere with re-epithelialization",
"        </p>",
"        <p>",
"         Can be used with SSD",
"        </p>",
"       </td>",
"       <td>",
"        Deep burns",
"       </td>",
"       <td>",
"        Skin hypersensitivity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Povidone-iodine",
"       </td>",
"       <td>",
"        <p>",
"         Controversial - toxic to fibroblasts",
"        </p>",
"        <p>",
"         Reduces cell proliferation",
"        </p>",
"       </td>",
"       <td>",
"        Only when no other agent is available",
"       </td>",
"       <td>",
"        <p>",
"         Children under two years",
"        </p>",
"        <p>",
"         Pregnant",
"        </p>",
"        <p>",
"         Breast feeding",
"        </p>",
"        <p>",
"         Thyroid disorders",
"        </p>",
"        <p>",
"         Signs of re-epithelialization",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Painful",
"        </p>",
"        <p>",
"         Skin hypersensitivities",
"        </p>",
"        <p>",
"         Chemical burn",
"        </p>",
"        <p>",
"         Iodine toxicity",
"        </p>",
"        <p>",
"         Renal failure",
"        </p>",
"        <p>",
"         Acidosis",
"        </p>",
"        <p>",
"         Anaphylaxis",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14477=[""].join("\n");
var outline_f14_8_14477=null;
var title_f14_8_14478="Classification of non-5q SMAs";
var content_f14_8_14478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Simplified classification of non-5q spinal muscular atrophies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease/phenotype, selected distinguishing features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene/locus",
"       </td>",
"       <td class=\"subtitle1\">",
"        OMIM designations",
"       </td>",
"       <td class=\"subtitle1\">",
"        MIM number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Distal spinal muscular atrophy/distal hereditary motor neuropathy or neuronopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SMA with respiratory distress or diaphragmatic SMA",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        IGHMBP2",
"       </td>",
"       <td>",
"        SMARD1/HMN6/DSMA1",
"       </td>",
"       <td>",
"        604320",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal HMN",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        9p21.1-p12",
"       </td>",
"       <td>",
"        DSMA2/HMNJ",
"       </td>",
"       <td>",
"        605726",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal SMA",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        11q13",
"       </td>",
"       <td>",
"        DSMA3/HMN3/HMN4",
"       </td>",
"       <td>",
"        607088",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower motor neuron syndrome with childhood onset",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        PLEKHG5",
"       </td>",
"       <td>",
"        DSMA4",
"       </td>",
"       <td>",
"        611067",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal HMN/SMA, juvenile",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        7q34-q36",
"       </td>",
"       <td>",
"        HMN1",
"       </td>",
"       <td>",
"        182960",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal adult HMN, Type IIA",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        HSPB8",
"       </td>",
"       <td>",
"        HMN2A",
"       </td>",
"       <td>",
"        158590",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal HMN, Type IIB",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        HSPB1",
"       </td>",
"       <td>",
"        HMN2B",
"       </td>",
"       <td>",
"        608634",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal HMN, Type IIC",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        HSPB3",
"       </td>",
"       <td>",
"        HMN2C",
"       </td>",
"       <td>",
"        613376",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal SMA with upper-limb predominance, Type VA",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        GARS",
"       </td>",
"       <td>",
"        HMN5",
"       </td>",
"       <td>",
"        600794",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Charcot-Marie-Tooth disease 2D",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        GARS",
"       </td>",
"       <td>",
"        CMT2D",
"       </td>",
"       <td>",
"        601472",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal SMA with upper-limb predominance, Type VB",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        BSCL2",
"       </td>",
"       <td>",
"        HMN5",
"       </td>",
"       <td>",
"        600794",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Silver spastic paraplegia syndrome",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        BSCL2",
"       </td>",
"       <td>",
"        SPG17",
"       </td>",
"       <td>",
"        270685",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal HMN with vocal cord paralysis",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        2q14",
"       </td>",
"       <td>",
"        HMN7A",
"       </td>",
"       <td>",
"        158580",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal HMN with vocal cord paralysis",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        DCTN1",
"       </td>",
"       <td>",
"        HMN7B",
"       </td>",
"       <td>",
"        607641",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Proximal spinal muscular atrophy (+/- distal involvement)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SMA with late-onset, Finkel type",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        VAPB",
"       </td>",
"       <td>",
"        ALS8",
"       </td>",
"       <td>",
"        608627",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital SMA with contractures/SMA, congenital, nonprogressive, with lower limb predominance",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        TRPV4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        600175",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scapuloperoneal SMA",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        TRPV4",
"       </td>",
"       <td>",
"        SPSMA",
"       </td>",
"       <td>",
"        181405",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Charcot-Marie-Tooth, Type 2C",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        TRPV4",
"       </td>",
"       <td>",
"        HMSN2C",
"       </td>",
"       <td>",
"        606071",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SMA with lower extremity predominance (early onset)",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        DYNC1H1",
"       </td>",
"       <td>",
"        SMALED",
"       </td>",
"       <td>",
"        158600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HMSN, proximal (Okinawa type)",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        3q13",
"       </td>",
"       <td>",
"        HMSNP",
"       </td>",
"       <td>",
"        604484",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Other non-5q spinal and bulbar muscular atrophies, SMA plus types",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lethal arthrogryposis with anterior horn cell disease",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        GLE1",
"       </td>",
"       <td>",
"        LAAHD",
"       </td>",
"       <td>",
"        611890",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lethal congenital contracture syndrome 1",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        GLE1",
"       </td>",
"       <td>",
"        LCCS1",
"       </td>",
"       <td>",
"        253310",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pontocerebellar hypoplasia with SMA",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        VRK1",
"       </td>",
"       <td>",
"        PCH1",
"       </td>",
"       <td>",
"        607596",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brown-Vialetto-Van Laere syndrome",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        C20ORF54",
"       </td>",
"       <td>",
"        BVVLS",
"       </td>",
"       <td>",
"        211530",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fazio-Londe disease, bulbar palsy",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        C20ORF54",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        211500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spinal and bulbar muscular atrophy (Kennedy disease)",
"       </td>",
"       <td>",
"        X-linked recessive",
"       </td>",
"       <td>",
"        Androgen receptor",
"       </td>",
"       <td>",
"        SMAX1/SBMA",
"       </td>",
"       <td>",
"        313200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infantile SMA with arthrogryposis",
"       </td>",
"       <td>",
"        X-linked recessive",
"       </td>",
"       <td>",
"        UBE1",
"       </td>",
"       <td>",
"        SMAX2",
"       </td>",
"       <td>",
"        301830",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal SMA, X-linked",
"       </td>",
"       <td>",
"        X-linked recessive",
"       </td>",
"       <td>",
"        ATP7A",
"       </td>",
"       <td>",
"        SMAX3",
"       </td>",
"       <td>",
"        300489",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Distal HMN: distal hereditary motor neuropathy or neuronopathy; DSMA: distal spinal muscular atrophy; SMA: spinal muscular atrophy.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Darras BT. Non-5q spinal muscular atrophies: the alphanumeric soup thickens. Neurology 2011; 77:31. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"     <br>",
"      Additional data from:",
"      <a href=\"file://www.ncbi.nlm.nih.gov/omim\" style=\"FONT-STYLE: italic\">",
"       Online Inheritance in Man",
"      </a>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14478=[""].join("\n");
var outline_f14_8_14478=null;
var title_f14_8_14479="LUL atelectasis CT";
var content_f14_8_14479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of left upper lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The atelectatic left upper lobe (white arrow) is in close apposition to the anterior chest wall and the mediastinum. Occlusion of the left upper lobe bronchus is visible (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_8_14479=[""].join("\n");
var outline_f14_8_14479=null;
